[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 236
1. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


2. Depondt J, Shabana el-H, Walker F, Pibouin L, Lezot F, Berdal A: Nasal inverted papilloma expresses the muscle segment homeobox gene Msx2: possible prognostic implications. Hum Pathol; 2008 Mar;39(3):350-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal inverted papilloma is a rare benign tumor of epithelial origin with aggressive evolution, bone destruction, recurrence, and malignant transformation.
  • The protein expression level was directly and significantly associated with tumor recurrence.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Homeodomain Proteins / biosynthesis. Nose Neoplasms / genetics. Nose Neoplasms / metabolism. Papilloma, Inverted / genetics. Papilloma, Inverted / metabolism
  • [MeSH-minor] Acid Phosphatase / metabolism. Adult. Aged. Female. Gene Expression. Genes, Homeobox / physiology. Humans. Immunohistochemistry. Isoenzymes / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. RANK Ligand / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187185.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / MSX2 protein; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / TNFSF11 protein, human; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


3. Tang Y, Wang L, Zhang P, Wei H, Gao R, Liu X, Yu Y, Wang L: Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol; 2010 Dec;17(12):1903-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
  • Mucin 1 (MUC1), a tumor-associated antigen, is a transmembrane glycoprotein expressed by normal epithelial cells and overexpressed by carcinomas of epithelial origin.
  • Autoantibodies against MUC1 are often found in circulation, either free or bound to immune complexes, which might contribute to limit tumor outgrowth and dissemination by antibody-dependent cell-mediated cytotoxicity, and were found favorably predictive of survival in early breast cancer patients.
  • The results showed that more patients with benign breast tumors (P = 0.001) and breast cancer patients before primary treatment (P = 0.010) were found to have anti-MUC1 IgG than healthy women; anti-MUC1 IgG before primary treatment was found more than after primary treatment (P = 0.016) in breast cancer patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay / methods. Escherichia coli / genetics. Female. Humans. Middle Aged. Sensitivity and Specificity. Tandem Repeat Sequences

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 1;96(9):3147-53 [11049996.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):589-94 [10673204.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):1-11 [11759823.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1217-22 [11953875.001]
  • [Cites] Eur J Cancer. 2002 Jun;38(9):1189-93 [12044504.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):97-100 [12455059.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1130-9 [12966437.001]
  • [Cites] Breast Cancer Res Treat. 2003 Oct;81(3):195-207 [14620915.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Urologe A. 1990 Mar;29(2):77-86 [2158684.001]
  • [Cites] Immunol Lett. 1993 Feb;35(2):163-8 [7685318.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2856-60 [7514493.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1325-31 [8869094.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12492-4 [9139698.001]
  • [Cites] Tumour Biol. 1998;19(3):186-95 [9591045.001]
  • [Cites] J Gastroenterol. 1998 Jun;33(3):354-61 [9658314.001]
  • [Cites] Cancer Immunol Immunother. 1998 Jul;46(5):245-52 [9690452.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):570-1 [16164922.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1324-36 [16619287.001]
  • [Cites] BMC Cancer. 2006;6:253 [17064405.001]
  • [Cites] Histol Histopathol. 2007 Aug;22(8):905-22 [17503348.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3060-9 [18483372.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):735-44 [18594319.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1357-63 [18561323.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):574-83 [10653872.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):112-20 [11471893.001]
  • (PMID = 20876819.001).
  • [ISSN] 1556-679X
  • [Journal-full-title] Clinical and vaccine immunology : CVI
  • [ISO-abbreviation] Clin. Vaccine Immunol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ PMC3008176
  •  go-up   go-down


Advertisement
4. Mentzel T: [Epithelioid sarcoma: morphologic variants and differential diagnosis]. Pathologe; 2010 Mar;31(2):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid sarcoma: morphologic variants and differential diagnosis].
  • Epithelioid sarcoma represents a rare sarcoma with a poor long-term prognosis that arises predominantly on the distal extremities of young adult patients, often mimicking a benign, non-neoplastic condition.
  • Histologically, epithelioid sarcoma is characterized by a multinodular growth with central necrosis, and the neoplasms are composed of relatively uniform epithelioid tumour cells showing a coexpression of vimentin, epithelial membrane antigen and pancytokeratin, and in about half of the cases of CD34.
  • Interestingly, most cases of epithelioid sarcoma show a loss of INI1, whereas the inactivation of the tumour suppressor gene SMARCB1/INI1 is only rarely caused by mutation.
  • The proximal variant of epithelioid sarcoma is composed of confluent sheets of enlarged epithelioid and rhabdoid tumour cells and represents the morphological progression of this entity.
  • The fibroma-like variant of epithelioid sarcoma as well as the angiomatoid and myxoid variants of epithelioid sarcoma are rare morphological variants and need to be considered in the differential diagnosis of other benign and malignant neoplasms.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Prognosis

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2009 Sep;40(9):1361-2; author reply 1362-4 [19683621.001]
  • [Cites] Am J Clin Pathol. 2009 Feb;131(2):222-7 [19141382.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4012-9 [15899790.001]
  • [Cites] Hum Pathol. 1999 Aug;30(8):934-42 [10452506.001]
  • [Cites] Cancer. 1970 Nov;26(5):1029-41 [5476785.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):349-55 [18973917.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):542-50 [19033866.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):99-105 [17197925.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(3):271-8 [1900974.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):655-63 [11454997.001]
  • [Cites] Histopathology. 2001 Dec;39(6):641-3 [11903586.001]
  • [Cites] Am J Surg Pathol. 1985 Apr;9(4):241-63 [4014539.001]
  • [Cites] Adv Anat Pathol. 2006 May;13(3):114-21 [16778474.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1382-95 [1371711.001]
  • [Cites] Histopathology. 2010 Nov;57(5):753-9 [21083605.001]
  • [Cites] Am J Surg Pathol. 2007 Dec;31(12):1813-24 [18043035.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):48-57 [12502927.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1168-74 [18580682.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):130-46 [9042279.001]
  • [Cites] Int J Surg Pathol. 2009 Apr;17(2):147-52 [18480401.001]
  • (PMID = 19997734.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 21
  •  go-up   go-down


5. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q: Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med; 2008;31(1):E8-E15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
  • The purpose of this study is to investigate the expression levels of Ki-67 and PCNA in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their potential on the early diagnosis of PCa.
  • METHODS: Human prostate cancer cell lines LNCaP and PC-3, human normal prostate epithelial cell line HuPEC, tissues from patients with PCa (121 cases) and BPH (45) and 36 normal cases were examined for the expression of Ki-67 and PCNA by Reverse Transcription-Polymerase Chain Reaction (RT-PCR).
  • Compared with BPH, the ratio of Ki-67 and PCNA expressed in tumour tissue was increased (P < 0.05).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Gene Expression Regulation, Neoplastic. Ki-67 Antigen / biosynthesis. Proliferating Cell Nuclear Antigen / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction


6. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This overview covers epithelial, stromal and mesenchymal malignancies of the body of the uterus, excluding the cervix.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • Some types of mixed epithelial and stromal neoplasm are described and contrasted with carcinosarcoma.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


7. Rego MF, Navarrete MA, Facina G, Falzoni R, Silva R, Baracat EC, Nazario AC: Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle. Cell Prolif; 2009 Apr;42(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Fibroadenoma is the most common benign mammary condition among women aged 35 or younger.
  • Expression of Ki-67 antigen has been used to compare proliferative activity of mammary fibroadenoma epithelium in the follicular and luteal phases of the menstrual cycle.
  • MATERIALS AND METHODS: Ninety eumenorrheic women were selected for tumour excision; they were assigned to either of the two groups, according to their phase of menstrual cycle.
  • At the end of the study, 75 patients with 87 masses were evaluated by epithelial cell Ki-67 expression, blind (no information given concerning group to which any lesion belonged).
  • Median tumour size was 2.0 cm and no relationship between proliferative activity and nodule diameter was observed.
  • Average values for expression of Ki-67 (per 1000 epithelial cells) in follicular and luteal phases were 27.88 and 37.88, respectively (P = 0.116).
  • CONCLUSION: Our findings revealed that proliferative activities in the mammary fibroadenoma epithelium did not present a statistically significant difference in the follicular and luteal phases.
  • The present study contributes to clarifying that fibroadenoma is a neoplasm and does not undergo any change in the proliferative activity during the menstrual cycle.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317807.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


8. Leung TK, Huang PJ, Lee CM, Chen CS, Wu CH, Chao JS: Can breast magnetic resonance imaging demonstrate characteristic findings of preoperative ductal carcinoma in situ in Taiwanese women? Asian J Surg; 2010 Jul;33(3):143-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively collected data from 13 cases of benign intraductal and early-stage malignant lesions to observe the capability of MPR, ESP and kinetic curve techniques to diagnose early lesions differentially.
  • We analysed early ductal lesions, such as intraductal epithelial hyperplasia, intraductal papilloma, ductal carcinoma in situ and small focal invasive ductal carcinoma.
  • The tumour size estimated by MRI was accurate in 6 cases, but overestimated in seven.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Asian Surgical Association. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21163412.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Scattoni V, Montironi R, Mazzucchelli R, Freschi M, Nava L, Losa A, Terrone C, Scarpa RM, Montorsi F, Pappagallo G, Rigatti P: Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int; 2006 Jul;98(1):54-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgical specimens were assessed for the histopathological features of cancer, HGPIN and benign epithelium in a blinded manner.
  • RESULTS: Compared with the bicalutamide-treated group, the ratio of stroma to epithelium, evaluated by visual microscopic assessment in the normal epithelium of the three prostate zones, was significantly lower in the control group, at 2.27 (sd 1.13), than in the treated group, at 1.87 (sd 0.72) (P = 0.048).
  • The mean (sd) tumour volume was significantly lower in the bicalutamide-treated than in the control group, at 0.914 (0.13) vs 1.47 (0.24) mL (P = 0.044).
  • CONCLUSIONS: Involution and epithelial shrinkage of prostate cancer and HGPIN were evident after neoadjuvant treatment with bicalutamide 150 mg.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831143.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Ungari C, Paparo F, Colangeli W, Iannetti G: Parotid glands tumours: overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms. Eur Rev Med Pharmacol Sci; 2008 Sep-Oct;12(5):321-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid glands tumours: overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms.
  • Salivary gland tumours are uncommon, representing less than 6% of head and neck neoplasm.
  • Pleomorphic adenoma is the most common benign epithelial salivary gland neoplasm, comprising 50%-74% of all parotid tumours.
  • It is followed by Warthin's tumour (4-14%).
  • The authors retrospectively reviewed 282 eligible patients surgically treated for parotid gland tumours in the last 10 years, focusing on 231 benign epithelial neoplasms.
  • The diagnosis of a parotid gland neoplasm must be considered in any patient presenting with a lump near the mandible.
  • Smoking habit is important in Warthin's tumour pathogenesis.
  • Tumour pseudopodia and capsule ruptures are recognised factors involved in pleomorphic adenoma recurrences but also tumour multicentricity might play an important role.
  • [MeSH-major] Epithelium / surgery. Parotid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024217.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A: Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol; 2006 Feb;19(2):307-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
  • NGFR is reported to act as a tumour suppressor, negatively regulating cell growth and proliferation.
  • NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype.
  • Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR.
  • NGFR expression in invasive tumours significantly correlated with that of cytokeratins 5/6 (P<0.05), 14 (P<0.0001) and 17 (P<0.0005) and EGFR (P<0.0001) and displayed an inverse correlation with oestrogen and progesterone receptors (both, P<0.0001).
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Keratin-14. Keratin-5. Keratin-6. Keratins / analysis. Myoepithelioma / metabolism. Myoepithelioma / pathology. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Nerve Growth Factor. Receptors, Progesterone / analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424897.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
  •  go-up   go-down


12. Gamlem H, Nordstoga K, Glattre E: Canine neoplasia--introductory paper. APMIS Suppl; 2008;(125):5-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paper gives a brief introduction to canine oncology, including its comparative aspects as basis for recording tumours in the animal kingdom.
  • In an abbreviated presentation of the Norwegian Canine Cancer Project for the years 1990-1998, the data (n=14,401) were divided into age groups, each of two years, into different categories of tumours, and into age and gender.
  • As expected, cutaneous histiocytoma was the dominant tumour type in both sexes during the two first years of life.
  • In the age group 2-3.99 years histiocytoma was still the largest group in males, but was surpassed by benign epithelial skin tumours in females.
  • After the age of 4 years, benign epithelial skin tumours constituted the greatest circumscribed group in males, and mammary tumours in females, although the summated other tumours, not explained in this survey, dominated overall in males.
  • While mastocytoma was the most common tumour and non-Hodgkin's lymphoma the second most common during the two first years of life in females, the situation was reversed in males.
  • Later, mammary tumours dominated in females, while different tumour types not further specified in this summarized report dominated in males, until the end of the age registration (above 14 years).
  • Number, sex and location of most common tumours are shown in a tabular outline.
  • Comparative aspects between human and dog tumours are considered: mammary and testicular neoplasia seemed more frequent in dogs than in humans in Norway, while intestinal, pulmonary and prostatic malignancies were less common in dogs.
  • In our study, vascular tumours and tumour-like lesions constituted about 3% of the total data.
  • As benign vascular tumours are incompletely reported to the human Cancer Registry, no dependable comparison may be made, but malignant vascular tumours have been on the rise during the last decades in the Norwegian human population, more so in men then in women.
  • Finally, the article deals briefly with the development of endothelial cells, and the sparse information on causal factors of vascular tumours.
  • [MeSH-major] Dog Diseases / epidemiology. Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385278.001).
  • [ISSN] 0903-465X
  • [Journal-full-title] APMIS. Supplementum
  • [ISO-abbreviation] APMIS Suppl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 55
  •  go-up   go-down


13. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


14. Kernek KM, Koch MO, Daggy JK, Juliar BE, Cheng L: The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence. J Clin Pathol; 2005 Jul;58(7):725-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence.
  • BACKGROUND: Serum prostate specific antigen (PSA) increases after radical prostatectomy are thought to indicate recurrent disease, although some suggest they result from benign prostatic epithelial tissue left at surgical margins.
  • AIMS: To investigate whether presence, location, and extent of benign prostatic tissue at radical prostatectomy surgical margins influence patient outcome.
  • The total length of benign prostatic tissue at the margins, measured for each location using an ocular micrometer, was obtained by summing the length of all positive sites.
  • The presence, anatomical location, and extent of benign prostatic tissue at the margin were correlated with clinicopathological characteristics and postoperative PSA increases.
  • RESULTS: Fifty five cases had benign prostatic glandular tissue at the surgical margin.
  • The most frequent location of benign prostatic tissue was the apex (40 patients).
  • Presence, anatomical location, and length of benign prostatic tissue at the margin were not significantly associated with age, preoperative PSA, prostate weight, pathological stage, tumour volume, largest tumour dimension, Gleason score, extraprostatic extension, seminal vesical invasion, tumour multifocality, perineural invasion, or PSA recurrence.
  • CONCLUSIONS: Benign prostatic tissue was frequently found in margins of apex and bladder base, but uncommon in the anterior or posterior prostate.
  • The presence of benign prostatic tissue at surgical margins had no prognostic relevance.
  • [MeSH-minor] Adult. Age Factors. Aged. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Prostatectomy. Recurrence


15. Gümgüm S, Hoşgören B: Clinical and radiologic behaviour of ameloblastoma in 4 cases. J Can Dent Assoc; 2005 Jul-Aug;71(7):481-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is a benign but locally aggressive epithelial odontogenic neoplasm.
  • It represents 1% of all tumours of the jaw bone.
  • We describe the clinical and radiologic behaviour of ameloblastoma and discuss treatment protocols and the possibility of conservative management of this tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026635.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


16. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology; 2007 Dec;70(6):1225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
  • Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression.
  • METHODS: RNA from laser capture microdissected (LCM) tumor and benign epithelial cells from radical prostatectomy specimens of 115 hormone-naive patients were studied.
  • A ratio of the expression of AR gene, normalized to GAPDH gene expression in the same specimens, was compared in tumor and benign epithelial cells (tumor-to-benign ratio) and correlated with clinicopathologic features.
  • RESULTS: Paired t test analysis revealed a 62% lower AR expression in tumor tissue compared with benign tissue (P = 0.0005).
  • However, multivariate Cox proportional hazards regression analysis of time to PSA recurrence revealed that higher tumor cell associated AR expression (continuous, log-transformed), significantly increases odds of prostate-specific antigen (PSA) recurrence (P = 0.0139) when controlling for age at surgery, race, time from diagnosis to surgery, risk stratification, pathologic T stage, Gleason sum, and margin status.
  • CONCLUSIONS: Quantitative determination of AR gene expression levels in prostate epithelial cells may be useful for predicting PSA recurrence.


17. Panchal L, Vaideeswar P, Kathpal D, Madiwale CV, Prabhat DP: Sino-nasal epithelial tumours: a pathological study of 69 cases. J Postgrad Med; 2005 Jan-Mar;51(1):30-4; discussion 34-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sino-nasal epithelial tumours: a pathological study of 69 cases.
  • BACKGROUND: Epithelial neoplasms are uncommon lesions affecting the sino-nasal tract.
  • AIM: To study the incidence, mode of presentation and histological types of sino-nasal epithelial tumours in the surgical pathology material.
  • SETTING AND DESIGN: Retrospective retrieval of all sino-nasal tumours and analysis of epithelial tumours.
  • MATERIALS AND METHODS: All sino-nasal epithelial tumours, biopsied or surgically excised over a period of ten years, were studied.
  • The tumours were classified as benign or malignant.
  • RESULTS: In ten years, there were 120 sino-nasal tumours representing 0.14% of all the surgical specimens received.
  • Sixty-nine epithelial tumours (59.2%) outnumbered the non-epithelial tumours and were diagnosed on the basis of histopathology.
  • Twenty were benign and 49 malignant; occurring predominantly in males.
  • Benign lesions included four squamous papillomas and 16 inverted papillomas, with recurrence in three inverted papillomas (21%).
  • Squamous cell carcinomas were the commonest among malignant tumours and four of these were associated with inverted or cylindrical cell papilloma.
  • The second most frequent malignant tumour was adenoid cystic carcinoma with eight cases.
  • CONCLUSION: Sino-nasal epithelial tumours are rare lesions, with male preponderance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793335.001).
  • [ISSN] 0022-3859
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Ulusan S, Bal N, Kizilkilic O, Bolat F, Yildirim S, Yildirim T, Niron EA: Case report: solid-pseudopapillary tumour of the pancreas associated with dorsal agenesis. Br J Radiol; 2005 May;78(929):441-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: solid-pseudopapillary tumour of the pancreas associated with dorsal agenesis.
  • Solid-pseudopapillary tumour of the pancreas is a rare benign or low-grade malignant epithelial tumour; its association with pancreatic dorsal agenesis has been reported only once before.
  • We present the radiological and histological findings of a case of pancreatic solid-pseudopapillary tumour associated with total pancreatic dorsal agenesis.
  • Radiological findings showed absence of the dorsal pancreas and an 8 cm x 6 cm diameter tumour arising from the head of the pancreas.
  • She underwent successful complete resection of the tumour.
  • Histopathology revealed a diagnosis of solid-pseudopapillary tumour.


19. Hayes BD, O'Doherty A, Quinn CM: Correlation of needle core biopsy with excision histology in screen-detected B3 lesions: the Merrion Breast Screening Unit experience. J Clin Pathol; 2009 Dec;62(12):1136-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although most NCBs are B2 (benign) or B5 (malignant), some fall into the B3 category of "uncertain malignant potential".
  • The NCB pathology reports were reviewed and the diagnosis correlated with excision histology; the latter was classified as benign, atypical or malignant.
  • The most frequent lesions on NCB were radial scar (RS; n = 57), atypical intraductal epithelial proliferation (AIDEP; n = 25) and papillary lesion (n = 24).
  • The final diagnosis was malignant in 22 patients (16%), atypical in 40 (28%) and benign in 79 (56%).
  • The lesion-specific PPVs were: lobular neoplasia 50%, AIDEP 32%, columnar cell lesion with atypia 12.5%, RS 12.3%, papillary lesion 8.3%, suspected phyllodes tumour 7.7%, and spindle cell lesion 0%.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19946101.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Franklin RB, Feng P, Milon B, Desouki MM, Singh KK, Kajdacsy-Balla A, Bagasra O, Costello LC: hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer; 2005 Sep 09;4:32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The normal peripheral zone glandular epithelium has the unique function of accumulating high levels of zinc.
  • The lost ability of the neoplastic epithelial cells to accumulate zinc is a consistent factor in their development of malignancy.
  • RESULTS: hZIP1 gene expression, ZIP1 transporter protein, and cellular zinc were prominent in normal peripheral zone glandular epithelium and in benign hyperplastic glands (also zinc accumulating glands).
  • In contrast, hZIP1 gene expression and transporter protein were markedly down-regulated and zinc was depleted in adenocarcinomatous glands and in prostate intra-epithelial neoplastic foci (PIN).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. CITRIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7 [12829793.001]
  • [Cites] Prostate. 1999 Aug 1;40(3):200-7 [10398282.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):253-60 [12966353.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):187-95 [14568174.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2258-62 [14634392.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):546-55 [14760076.001]
  • [Cites] Prostate. 2004 Mar 1;58(4):374-81 [14968438.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:316-20 [15033742.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13293-6 [14966140.001]
  • [Cites] Eur Urol. 2004 Jun;45(6):683-91 [15149739.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2004;7(2):111-7 [15175662.001]
  • [Cites] J Physiol. 2004 Jun 15;557(Pt 3):719-31 [15090606.001]
  • [Cites] Tumour Biol. 2004 May-Jun;25(3):134-40 [15361710.001]
  • [Cites] Cancer Res. 1967 Aug;27(8):1348-53 [4167368.001]
  • [Cites] Invest Urol. 1969 Jan;6(4):345-7 [5773519.001]
  • [Cites] Exp Mol Pathol. 1973 Oct;19(2):139-42 [4127820.001]
  • [Cites] Br J Cancer. 1979 Jun;39(6):700-4 [87214.001]
  • [Cites] Urol Res. 1982;10(6):301-3 [6186062.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1388-92 [2465818.001]
  • [Cites] Biochem Soc Trans. 2005 Feb;33(Pt 1):237-40 [15667316.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3028-35 [15687339.001]
  • [Cites] Front Biosci. 2005;10:2230-9 [15970489.001]
  • [Cites] Mitochondrion. 2005 Jun;5(3):143-53 [16050980.001]
  • [Cites] Mol Cell Biochem. 2005 Dec;280(1-2):1-8 [16511951.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5560-4 [10681536.001]
  • [Cites] J Inorg Biochem. 2000 Jan 30;78(2):161-5 [10766339.001]
  • [Cites] Mol Urol. 2000 Spring;4(1):31-6 [10851304.001]
  • [Cites] Am J Hum Genet. 2000 Dec;67(6):1367-75 [11067781.001]
  • [Cites] Oncology. 2000 Nov;59(4):269-82 [11096338.001]
  • [Cites] Prostate. 2002 Sep 1;52(4):311-8 [12210492.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):451-63 [12353259.001]
  • [Cites] Radiology. 1996 Mar;198(3):795-805 [8628874.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):28875-81 [9360955.001]
  • [Cites] Int Urol Nephrol. 1997;29(5):565-74 [9413764.001]
  • [Cites] Prostate. 1998 Jun 1;35(4):285-96 [9609552.001]
  • [Cites] Prostate. 1999 Feb 15;38(3):237-45 [10068348.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17499-504 [10364181.001]
  • [Cites] J Inorg Biochem. 2003 Aug 1;96(2-3):435-42 [12888280.001]
  • (PMID = 16153295.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / PHS HHS / / R01-097714; United States / NCI NIH HHS / CA / CA 79903; United States / NCI NIH HHS / CA / R01 CA079903; United States / NCI NIH HHS / CA / R01 CA071207; United States / NCI NIH HHS / CA / CA 71207
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cation Transport Proteins; 0 / RNA, Messenger; 0 / SLC39A1 protein, human; 2968PHW8QP / Citric Acid; J41CSQ7QDS / Zinc
  • [Other-IDs] NLM/ PMC1243239
  •  go-up   go-down


21. Hall GH, Turnbull LW, Bedford K, Richmond I, Helboe L, Atkin SL: Neuropilin-1 and VEGF correlate with somatostatin expression and microvessel density in ovarian tumours. Int J Oncol; 2005 Nov;27(5):1283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropilin-1 and VEGF correlate with somatostatin expression and microvessel density in ovarian tumours.
  • Vascular endothelial growth factor (VEGF), is an angiogenic growth factor, expressed more highly in malignant than benign ovarian tumours.
  • Neuropilin-1, which can act as a VEGF receptor has been shown to be associated with tumour angiogenesis in some cancer systems.
  • We used immunohistochemistry to demonstrate expression of Neuropilin-1 in 63 malignant and 35 benign ovarian tumours and compared it to VEGF, Flt, Flk, SST expression and tumour microvessel density (MVD).
  • Neuropilin-1 was expressed in 34/63 malignant and 22/35 benign lesions.
  • VEGF, Flt, Flk and SST were expressed more highly in the epithelium of malignant and the vessels of benign lesions.
  • VEGF expression correlated with SST expression in the epithelium (p<0.001) and the vessels (p<0.001), this co-expression was confirmed by dual immunostaining.
  • The MVD for malignant lesions was higher than benign (p<0.001) and positively correlated to epithelial VEGF expression (p=0.001) and negatively correlated to vascular VEGF expression (p=0.025).
  • These results show that Neuropilin-1 is expressed in ovarian tumours and also show that VEGF and SST are co-expressed in the same tissue compartments raising the intriguing possibility that SST may be important in angiogenesis in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211223.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 144713-63-3 / Neuropilin-1; 51110-01-1 / Somatostatin
  •  go-up   go-down


22. Tse GM, Chaiwun B, Lau KM, Scolyer R, Lee CS, Karim RZ, Putti TC, Law BK, Lui PC, Tan PH: Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol; 2007 Sep;60(9):1051-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours.
  • BACKGROUND AND AIMS: Endothelin-1 expression is increased in infiltrating duct carcinoma and is associated with larger tumour size, higher histological grade and lymphovascular permeation.
  • This has not been evaluated in phyllodes tumours, which are uncommon fibroepithelial lesions with potential for local recurrences or distant metastasis.
  • While the grading of phyllodes tumours depends on a combination of histological parameters, prediction of their behaviour remains difficult.
  • METHOD: A large series of 461 phyllodes tumours (291 benign, 115 borderline malignant and 55 frankly malignant) were evaluated for endothelin-1 expression in both the epithelial cells and stromal cells by immunohistochemistry; results were correlated with the tumour grade.
  • RESULTS: For benign phyllodes tumours, the epithelial staining of endothelin was negative, weak, moderate and strong in 6%, 26%, 15% and 53% of cases respectively; results were 4%, 18%, 19% and 59% respectively for borderline and 6%, 18%, 6% and 70% respectively for frankly malignant tumours.
  • For the stromal staining, the negative, weak, moderate and strong staining was 32%, 19%, 18% and 31% respectively for benign phyllodes, 24%, 13%, 10% and 53% respectively for borderline and 8%, 16%, 17% and 59% respectively for frankly malignant tumours.
  • There was correlation between epithelial and stromal staining, and the stromal staining correlated with histological features of stromal cellularity, stromal cell nuclear pleomorphism, margin status and stromal overgrowth.
  • CONCLUSION: These observations suggest a close relationship between the epithelial and stromal elements in phyllodes tumours; endothelin may play a significant role in the malignant progression of phyllodes tumours.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelin-1 / metabolism. Neoplasm Proteins / metabolism. Phyllodes Tumor / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / pathology. Epithelial Cells / metabolism. Female. Humans. Middle Aged. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):910-6 [8608483.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nature. 1988 Mar 31;332(6163):411-5 [2451132.001]
  • [Cites] FEBS Lett. 1988 Apr 25;231(2):440-4 [3282927.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):7856-61 [2542249.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] J Surg Oncol. 1990 Sep;45(1):46-51 [2166186.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1741-8 [1701822.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):141-7 [1309302.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):720-7 [9973223.001]
  • [Cites] Pathol Res Pract. 1998;194(2):97-104 [9584322.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4046-9 [1319837.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 30;375(1-3):133-8 [10443571.001]
  • [Cites] Histopathology. 1999 Aug;35(2):162-9 [10460662.001]
  • [Cites] Pathol Int. 1999 Sep;49(9):807-10 [10504552.001]
  • [Cites] Am J Clin Pathol. 2005 Apr;123(4):529-40 [15743740.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):129-38 [15863261.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Surg Oncol. 1995;4(6):309-15 [8809953.001]
  • [Cites] Histopathology. 2000 Feb;36(2):161-7 [10672062.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):51-61 [10708518.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Apr;22(4):422-31 [10745023.001]
  • [Cites] BJU Int. 2000 Apr;85 Suppl 2:45-8 [10781185.001]
  • [Cites] Eur J Immunol. 2002 Sep;32(9):2393-400 [12207323.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):21-8 [12497202.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1273-81 [12516960.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Pathol. 2003 May;200(1):59-64 [12692842.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4125-31 [14519635.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1007-13 [14559983.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2461-8 [15059899.001]
  • [Cites] Mod Pathol. 2004 Jul;17(7):827-31 [15044924.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1053-7 [15343505.001]
  • [Cites] Radiology. 1983 Feb;146(2):481-6 [6294737.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S1-4 [11078319.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:851-76 [11264479.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):734-40 [12118111.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • (PMID = 17158636.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1972415
  •  go-up   go-down


23. Sauer T, Pedersen MK, Ebeltoft K, Naess O: Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology; 2005 Aug;16(4):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The material consisted of 52 air-dried smears from fine needle aspirates of breast carcinomas, both primary and metastatic and smears from seven benign lesions.
  • The degree of staining was recorded as negative, reduced or full, with full expression meaning equivalent to the staining pattern found in the fibroadenomas used as benign control.
  • The control smears revealed a strong membrane and cytoplasmic positivity in all luminal epithelial cells.
  • In cases with reduced expression, the percentage of stained cells were usually high, and no smear showed <50% stained tumour cells.
  • Claudin-7 expression showed a significant correlation (P < 0.05) with grading, locoregional and distant metastases, nodal involvement and cellular cohesion in invasive carcinomas, but not with tumour size or subtype.
  • CONCLUSION: Reduced expression of Claudin-7 correlated with higher tumour grade, metastatic disease, including loco-regional recurrences and with cellular discohesion.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048505.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


24. Halldorsson A, Dissanaike S, Kaye KS: Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour. J Clin Pathol; 2005 Nov;58(11):1211-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour.
  • Alveolar adenomas are extremely rare, and are probably benign lung tumours of unknown histogenesis.
  • Although a positron emission tomography scan seemed to document the benign nature of the lesion, a thoracoscopic wedge resection was performed to alleviate the symptoms and verify the diagnosis.
  • The cystic cell linings were mostly indistinct, although areas of cuboidal epithelial cells were seen.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):155-9 [15173924.001]
  • [Cites] Pathologe. 1990 Jan;11(1):48-54 [2179944.001]
  • [Cites] Pathologe. 1996 Mar;17(2):150-3 [8650145.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):34-7 [8689607.001]
  • [Cites] Virchows Arch. 1996 Oct;429(2-3):101-8 [8917711.001]
  • [Cites] Virchows Arch. 1997 Feb;430(2):181-4 [9083522.001]
  • [Cites] Pol J Pathol. 2003;54(2):147-52 [14575424.001]
  • [Cites] Cesk Patol. 1997 May;33(2):49-52 [9340215.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):158-67 [10029443.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):1066-71 [3759064.001]
  • [Cites] Ann Pathol. 1999 Sep;19(4):325-8 [10544770.001]
  • [Cites] J Thorac Imaging. 2002 Apr;17(2):163-6 [11956369.001]
  • [Cites] Rontgenpraxis. 1997 Feb;50(2):29-30 [9173555.001]
  • (PMID = 16254114.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770767
  •  go-up   go-down


25. Zhou J, Ye F, Chen H, Lv W, Gan N: The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res; 2007 May-Jun;35(3):290-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines.
  • Expression of IL-10 in ovarian carcinoma, benign ovarian tumour, normal control tissues and ovarian carcinoma cell lines was detected by immunohistochemistry and Western blot analysis.
  • IL-10 concentrations in sera and ascites from patients with ovarian carcinoma, in sera from patients with benign ovarian tumour and normal controls, and in supernatants of ovarian carcinoma cell line cultures were measured by enzyme-linked immunosorbent assay.
  • The tissue level of IL-10 in ovarian carcinoma was significantly higher than in benign ovarian tumour and normal controls.
  • In patients with ovarian carcinoma the IL-10 level in ascitic fluid was significantly higher than in sera, and the serum IL-10 level in ovarian carcinoma was significantly higher than in benign ovarian tumour and normal controls.
  • [MeSH-major] Carcinoma / metabolism. Interleukin-10 / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Ascitic Fluid / metabolism. Blotting, Western. Cell Line, Tumor. Female. Humans. Middle Aged. Reference Values

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593856.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


26. Păun I, Mogoş D, Păun M, Teodorescu M, Florescu M, Tenovici M, Mogoş G: [Diseases mimicking advanced-stage epithelial ovarian cancer]. Chirurgia (Bucur); 2010 Jul-Aug;105(4):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diseases mimicking advanced-stage epithelial ovarian cancer].
  • [Transliterated title] Afecţiuni mimând cancerul ovarian epitelial în stadiu avansat.
  • This paper draws attention towards 3 cases with different pathologies all of which suggesting however both clinically and by imaging means as the most likely diagnosis advanced-stage epithelial ovarian cancer since all these three postmenopausal women had been admitted to the hospital with ascites, pelvic masses and deterioration of the physical wellbeing (fatigue, decreased appetite, weight loss, pallor).
  • Findings during exploratory laparotomy on all these three pacients included ascites (hemorragic in one case) diffuse tumorous implants throughout the abdominal and pelvic peritoneal surfaces (in two cases) and the ovarian tumour.
  • Postoperatively, the final histopathologic diagnoses consisted of primary peritoneal carcinoma (one pacient), peritoneal tuberculosis (TB, one pacient) and hepatic cirrosis with an incidental benign adnexial mass (one pacient).
  • Moreover, nonmalignant ovarian tumours were certified in all three cases under current presentation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Antitubercular Agents / therapeutic use. Ascites / diagnosis. Diagnosis, Differential. Diagnostic Errors. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy. Treatment Outcome


27. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • We identified a specific cell population characterized by the coexpression of nestin, MAP2, and GFAP within the invasion niche of the adamantinomatous subtype.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


28. Mirza S, Bradley PJ, Acharya A, Stacey M, Jones NS: Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. J Laryngol Otol; 2007 Sep;121(9):857-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Inverted papillomas are relatively rare, benign epithelial tumours of the nasal cavity which generate considerable interest because they are locally aggressive, have a tendency to recur and are associated with malignancy.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Papilloma, Inverted / epidemiology. Paranasal Sinus Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319993.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 69
  •  go-up   go-down


29. Ascani G, Messi M, Balercia P: [Surgical management of pleomorphic adenoma of the salivary glands: our experience]. G Chir; 2008 Aug-Sep;29(8-9):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pleomorphic adenoma is a benign epithelial tumour of adenoid structure preferentially arising from the parotid gland.
  • PATIENTS AND METHODS: This is an audit of a 15-year period where 347 pleomorphic adenomas of the salivary glands were treated by the authors.
  • The tumour occurred more often in females than in males (F:M=1.5).

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834565.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Capote-Moreno A, Acero J, García-Recuero I, Ruiz J, Serrano R, de Paz V: Giant aneurysmal bone cyst of the mandible with unusual presentation. Med Oral Patol Oral Cir Bucal; 2009 Mar;14(3):E137-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aneurysmal bone cysts are rare benign lesions of bone tissue, infrequent in craneofacial skeleton with regard to other structures like long bones or the spine.
  • We present a case of a 29-year-old Caucasian male with a big swelling in the left mandible associated to pain and rapid growth.
  • After selective embolization of the tumour, surgical resection was done with curettage and immediate reconstruction of the defect with an anterior iliac crest graft.
  • Aneurysmal bone cysts are non-neoplastic but locally aggressive tumours with occasional rapid growth that may be differentiated from other multilocular process like ameloblastoma, ossifying fibroma, epithelial cyst, giant cell granuloma and sarcomas.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Mandibular Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242394.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H: High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investig; 2007 Mar;11(1):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour-invasion like wound healing is characterised by the formation of an extracellular matrix with a high tenascin-C content.
  • Analysis using antibody BC2 indicates that especially the high-molecular tenascin-C (hm tn-C) variants are typically tumour-associated, while distribution in normal tissue is restrictive.
  • Conventional cytology produced four false-positives when identifying atypical cells in brush biopsies of inflammatory/benign hyperproliferative mucosa (specificity 96%), while 10 in 52 carcinomas and three of eight recurrences were not identified (sensitivity 78%).
  • Ten of these 13 non-identified tumours could be marked when adding the hm tn-C assay (increasing specificity to 99%).
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Tenascin / analysis
  • [MeSH-minor] Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Mouth Mucosa / pathology. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):986-90 [15094113.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):505-10 [10762653.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] J Oral Pathol Med. 2006 Sep;35(8):520; author reply 520-2 [16918607.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):719-22 [12209613.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252 [14515857.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] Biochem Cell Biol. 1997;75(6):759-69 [9599665.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):680-7 [9495234.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]
  • [Cites] J Oral Pathol Med. 1994 Nov;23(10):446-50 [7532219.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • [Cites] Gen Dent. 2002 Nov-Dec;50(6):500-3 [12572180.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]
  • (PMID = 17111122.001).
  • [ISSN] 1432-6981
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin
  •  go-up   go-down


32. Mumba E, Ali H, Turton D, Cooper K, Grayson W: Human papillomaviruses do not play an aetiological role in Müllerian adenosarcomas of the uterine cervix. J Clin Pathol; 2008 Sep;61(9):1041-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HPV status of the nine histologically proven tumours was investigated by non-isotopic in situ hybridisation (NISH) and PCR.
  • RESULTS: Neither the benign epithelial components nor the malignant stromal components of the 9 neoplasms harboured nuclear NISH signals for the HPV types investigated.
  • Amplimers of the HPV L1 gene were not detected by PCR in any of the tumours studied.
  • This suggests that a different histogenetic pathway for this rare tumour type must exist.


33. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • We here present the case of a 44-year-old woman with a lesion in the cauda equina that fulfilled the radiologic criteria of schwannoma and caused clinical symptoms for 3 years.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • These extraadrenal tumors are thought to arise from heterotopic adrenocortical tissue in the spinal cavity.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • To date, only five such intraspinal tumors have been observed.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • A view of the literature of these rare but probably underdiagnosed intraspinal tumors is given.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2005 Sep;60(9):953-9 [16124976.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):260-5 [12053045.001]
  • [Cites] Spinal Cord. 2007 Feb;45(2):183-6 [16505829.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):310-2 [11302638.001]
  • [Cites] J Pediatr Surg. 1980 Jun;15(3):289-92 [6103925.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Histopathology. 1997 Aug;31(2):167-73 [9279569.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):375-82 [9130983.001]
  • [Cites] J Med Case Rep. 2008 Jul 13;2:228 [18620603.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Histopathology. 1986 Mar;10(3):311-9 [2422107.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Jul-Aug;25(4):191-7 [17162526.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):756-9 [10981764.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kousar A, Hosein MM, Ahmed Z, Minhas K: Rapid sarcomatous transformation of an ameloblastic fibroma of the mandible: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep;108(3):e80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic fibrosarcoma (AFS) is a rare malignant odontogenic tumour regarded as the malignant counterpart of ameloblastic fibroma.
  • It is characterized by a benign epithelial component within a malignant fibrous stroma.
  • AFS is a locally aggressive neoplasm with extremely low potential for metastasis.
  • We report an extremely rare, rapidly progressive, and fatal case originating in the posterior mandible of a 20-year old female patient.
  • Initially histopathologically diagnosed as a benign lesion, it rapidly recurred with apparent transformation into a high-grade sarcoma over a period of 6 months.
  • This case emphasizes the need for a high element of suspicion about clinically ambiguous lesions.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Odontogenic Tumors / pathology. Sarcoma / pathology
  • [MeSH-minor] Brain Neoplasms / secondary. Fatal Outcome. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Masseter Muscle / pathology. Muscle Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Radiography, Panoramic. Skull Neoplasms / pathology. Sphenoid Bone / pathology. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716496.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


35. Watson JA, Watson CJ, McCrohan AM, Woodfine K, Tosetto M, McDaid J, Gallagher E, Betts D, Baugh J, O'Sullivan J, Murrell A, Watson RW, McCann A: Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum Mol Genet; 2009 Oct 1;18(19):3594-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have used PwR-1E benign prostate epithelial cells and an equivalently aged hypoxia-adapted PwR-1E sub-line to identify phenotypic and epigenetic consequences of chronic hypoxia in prostate cells.
  • These epigenetic signatures may represent an additional mechanism to promote and maintain a hypoxic-adapted cellular phenotype with a potential role in tumour development.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584087.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histones; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A
  •  go-up   go-down


36. Altemani A, Martins MT, Freitas L, Soares F, Araújo NS, Araújo VC: Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology; 2005 Jun;46(6):635-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CXPAs were classified into two main groups according to their predominant cellular component as detected by the panel of antibodies: (i) carcinomas with only epithelial differentiation (75% of the cases), and (ii) carcinomas with a myoepithelial component (25%).
  • CXPA with only epithelial differentiation showed two types of malignant areas in the part of the tumour that was confined by the PA capsule: (i) intraductal carcinoma areas characterized by ductal structures containing both benign myoepithelial cells positive for alpha-smooth muscle actin (alpha-SMA), vimentin and cytokeratin (CK)14 and proliferating atypical luminal cells reactive for CK7, CK8 and CK19, and (ii) carcinoma areas composed only of epithelial cells reactive for CK7, CK8 and CK19.
  • CONCLUSION: Most CXPAs consist only of epithelial cells that have an immunoprofile comparable to ductal luminal cells of PA.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Biomarkers, Tumor / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910594.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / KRT14 protein, human; 0 / KRT7 protein, human; 0 / Keratin-14; 0 / Keratin-7; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


37. Halbritter SA, Altermatt HJ, Caversaccio M, Bornstein MM: Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation. Quintessence Int; 2009 Feb;40(2):167-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation.
  • Cystadenomas are a rare, painless, and slow-growing benign epithelial tumor of the salivary gland.
  • This article describes the case of a papillary cystadenoma in the lower lip of a 46-year-old man.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169449.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Moreira PR, Guimarães MM, Gomes CC, Diniz MG, Brito JA, de Castro WH, Gomez RS: Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours. Arch Oral Biol; 2009 Oct;54(10):893-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours.
  • OBJECTIVE: The benign epithelial odontogenic tumours constitute a group of lesions derived from epithelial elements of the tooth-forming apparatus.
  • This group includes lesions of different biological behaviour, such as ameloblastoma, calcifying cystic odontogenic tumour (CCOT) and adenomatoid odontogenic tumour (AOT).
  • The aim of this study was to investigate the methylation status of P16, P21, P27, P53 and RB1 genes in epithelial odontogenic tumours.
  • A high percentage of the odontogenic tumours analysed showed methylation of the P21 gene, in contrast to dental follicles.
  • CONCLUSIONS: Epithelial odontogenic tumours show a distinct methylation profile in cell-cycle associated genes.
  • In addition to this, the current findings show that epigenetic alterations are common events in epithelial odontogenic tumours.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA Methylation / genetics. DNA, Neoplasm / metabolism. Neoplasm Proteins / genetics. Odontogenic Tumors / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Ameloblastoma / genetics. Ameloblastoma / metabolism. Dental Sac / metabolism. Epithelial Cells / metabolism. Humans. Odontogenic Cyst, Calcifying / genetics. Odontogenic Cyst, Calcifying / metabolism. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679296.001).
  • [ISSN] 1879-1506
  • [Journal-full-title] Archives of oral biology
  • [ISO-abbreviation] Arch. Oral Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  •  go-up   go-down


39. Swierzko AS, Florczak K, Cedzyński M, Szemraj J, Wydra D, Bak-Romaniszyn L, Emerich J, Sułowska Z: Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol Immunother; 2007 Jul;56(7):959-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mannan-binding lectin (MBL) in women with tumours of the reproductive system.
  • Additionally, samples from patients with other malignant and benign tumours of the reproductive tract were tested.
  • MBL-specific mRNA expression was detected in several normal and malignant ovarian tissues, as well as in ovarian epithelial cell lines.
  • MBL was detected in ascites and in the fluid of benign ovarian cysts.
  • However, it cannot be excluded that mbl-2 mutant alleles may be in linkage disequilibrium with an unidentified tumour susceptibility gene(s).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Flow Cytometry. Gene Expression. Gene Expression Profiling. Genotype. Haplotypes. Humans. Immunohistochemistry. Mannose-Binding Protein-Associated Serine Proteases / analysis. Mannose-Binding Protein-Associated Serine Proteases / metabolism. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131120.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mannose-Binding Lectin; EC 3.4.21.- / MASP2 protein, human; EC 3.4.21.- / Mannose-Binding Protein-Associated Serine Proteases
  •  go-up   go-down


40. Chung EM, Cube R, Lewis RB, Conran RM: From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors. Radiographics; 2010 May;30(3):801-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors.
  • Benign hepatic tumors in children include lesions that are unique to the pediatric age group and others that are more common in adults.
  • Infantile hemangioendothelioma, or infantile hepatic hemangioma, is a benign vascular tumor that may cause serious clinical complications.
  • The mesenchymal component or cystic component may predominate; this predominance determines the imaging appearance of the tumor.
  • Benign epithelial tumors that are common in adults may infrequently occur in childhood.
  • Knowledge of how the pathologic features of these tumors affect their imaging appearances helps radiologists offer an appropriate differential diagnosis and management plan.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462995.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Calcaterra R, Franco G, Valenzano M, Fazio R, Morrone A: Clinical features and treatment of dermatosis papulosa nigra in migrants to Italy. Skinmed; 2010 Jul-Aug;8(4):207-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatosis papulosa nigra (DPN) is a benign epithelial tumor that is common in dark-skinned people.
  • Therefore, even if DPN is a benign disease, the lesions are unaesthetic and the therapeutic options are quite inefficient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137605.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Miot HA, Miot LD, da Costa AL, Matsuo CY, Stolf HO, Marques ME: Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J; 2006;12(2):2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary keratoacanthoma (KA) is a common benign epithelial tumor of the skin characterized by rapid growth and a tendency toward spontaneous regression.
  • The exact etiology and classification of KA are a matter of debate.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638395.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Matsumura T, Yamaguchi T, Tochigi N, Wada T, Yamashita T, Hasegawa T: Angiomatoid fibrous histiocytoma including cases with pleomorphic features analysed by fluorescence in situ hybridisation. J Clin Pathol; 2010 Feb;63(2):124-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Angiomatoid fibrous histiocytoma (AFH) is a rare soft-tissue tumour of uncertain differentiation and low metastatic potential.
  • METHODS: Tumour samples from 10 patients were subjected to clinicopathological and immunohistochemical analysis and dual-colour fluorescence in situ hybridisation for EWSR1 and FUS with split-signal probes.
  • RESULTS: All cases showed clinical features (sites: extremities followed by trunk; age: adolescent to young adult), morphology (multinodular proliferation of spindle cells, lymphoid cuffs and pseudovascular spaces) and immunohistochemical results (more than half were positive for CD68, CD99, desmin and epithelial membrane antigen) typical of AFH.
  • Two patients developed distant metastases and died from the disease; tumours of these two patients showed focal proliferation of large pleomorphic cells with hyperchromatic nuclei and high proliferative activity (>10/10 high-power field and Ki-67 labelling index >10%).
  • [MeSH-major] Histiocytoma, Benign Fibrous / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adult. Calmodulin-Binding Proteins / genetics. Child. Child, Preschool. Female. Follow-Up Studies. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence / methods. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Recurrence, Local / genetics. RNA-Binding Protein FUS / genetics. RNA-Binding Proteins / genetics. Young Adult

  • Genetic Alliance. consumer health - Histiocytoma, angiomatoid fibrous.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154033.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calmodulin-Binding Proteins; 0 / EWSR1 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Protein FUS; 0 / RNA-Binding Proteins
  •  go-up   go-down


44. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol; 2010 May 01;28(13):2159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a multimarker assay for early detection of ovarian cancer.
  • PATIENTS AND METHODS: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays.
  • This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.
  • CONCLUSION: A panel of CA-125, HE4, CEA, and VCAM-1, after additional validation, could serve as an initial stage in a screening strategy for epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoassay. Mass Screening / methods. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Algorithms. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Data Interpretation, Statistical. Early Detection of Cancer. Epididymal Secretory Proteins / analysis. Female. Humans. Middle Aged. Monte Carlo Method. Neoplasm Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Vascular Cell Adhesion Molecule-1 / blood. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 May 1;28(13):2128-30 [20368556.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:418-34 [10800496.001]
  • [Cites] Life Sci. 2001 Jan 12;68(8):861-72 [11213356.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):643-50 [11237385.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Pathol. 2002 Apr;55(2):110-20 [11950960.001]
  • [Cites] J Cancer Res Clin Oncol. 1989;115(5):456-8 [2808485.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):133-7 [10461006.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37 [10067810.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Gynecol Oncol. 1988 Jun;30(2):265-73 [3163666.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4735-7 [9494598.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Dis Markers. 2007;23(5-6):419-31 [18057525.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2190-6 [10786683.001]
  • [Cites] Tumour Biol. 1993;14(2):105-15 [8392219.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4 [15904446.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):165-74 [11822989.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):528-34 [15717649.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4 [11176234.001]
  • [Cites] Cancer. 1975 May;35(5):1377-81 [47262.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):605-10 [12845660.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):131-40 [10411105.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4 [8297846.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] J Surg Oncol. 1990 Jun;44(2):97-9 [2355747.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2380-6 [11489816.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Mar;76(3):283-5 [9093148.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):61-79 [17275179.001]
  • [Cites] Semin Surg Oncol. 1994 Jul-Aug;10(4):242-8 [8091065.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Apr;99(4):329-32 [1581280.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1186-7 [7981074.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(3):265-312 [15307634.001]
  • [Cites] Clin Sci (Lond). 2006 Mar;110(3):279-91 [16464170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Gynecol Oncol. 1988 Jan;29(1):66-75 [3422208.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5 [10487660.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Medscape Womens Health. 1996 Nov;1(11):3 [9746655.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):23-35 [9511849.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):27-30 [9234916.001]
  • [Cites] Cytokine. 2009 Jan;45(1):44-9 [19058974.001]
  • [Cites] Biomed Biochim Acta. 1986;45(3):371-84 [3518711.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2743-6 [7532929.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):1024-9 [9307529.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2891-4 [9713482.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):135-40 [10843471.001]
  • [Cites] Fertil Steril. 2003 Oct;80(4):1068-9; author reply 1069-70 [14556841.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Nov;86(11):901-4 [116672.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Hum Reprod. 2005 Jan;20(1):117-21 [15513972.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):185-92 [12218299.001]
  • [Cites] Cancer Invest. 1995;13(2):227-38 [7874576.001]
  • [Cites] Immunol Invest. 2006;35(2):167-79 [16698675.001]
  • [Cites] Eur Cytokine Netw. 2009 Mar;20(1):21-6 [19318317.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):248-52 [9648596.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):379-84 [15645122.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 May 1;120(1):87-90 [15866092.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):201-7 [8031969.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6 [16985025.001]
  • [Cites] Am Fam Physician. 2003 Sep 15;68(6):1075-82 [14524394.001]
  • (PMID = 20368574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / CA105009; United Kingdom / Medical Research Council / / G9901012; United States / NCI NIH HHS / CA / R01 CA108990; United Kingdom / Medical Research Council / / G0801228; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Vascular Cell Adhesion Molecule-1; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC2860434
  •  go-up   go-down


45. Shah N, Tighe JV, Barrett AW, Kumar S, Allen JP: Bilateral intraparotid and extraparotid Warthin's tumours. Br J Oral Maxillofac Surg; 2007 Apr;45(3):238-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral intraparotid and extraparotid Warthin's tumours.
  • Warthin's tumour is a benign adenoma in the parotid gland, but extraparotid and synchronous bilateral Warthin's tumours may occur.
  • In this report, we describe a patient with simultaneous bilateral involvement of the parotid glands and neck by multiple Warthin's tumours, an occurrence not previously described.
  • [MeSH-minor] Aged. Epithelial Cells / pathology. Humans. Lymph Nodes / pathology. Male. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16207506.001).
  • [ISSN] 0266-4356
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


46. Hungermann D, Buerger H, Oehlschlegel C, Herbst H, Boecker W: Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells. BMC Cancer; 2005;5:92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
  • BACKGROUND: Adenomyoepithelial tumours and myoepithelial carcinomas of the breast are primarily defined by the presence of neoplastic cells with a myoepithelial immunophenotype.
  • Current classification schemes are based on purely descriptive features and an assessment of individual prognosis is still problematic.
  • METHODS: A series of 27 adenomyoepithelial tumours of the breast was analysed immunohistochemically with antibodies directed against various cytokeratins, p63, smooth muscle alpha-actin (SMA) and vimentin.
  • RESULTS: Immunohistochemically, all the tumours showed a constant expression of high molecular weight cytokeratins (Ck) Ck5 and Ck14, p63, SMA and vimentin.
  • With exception of one case diagnosed as myoepithelial carcinoma, all tested tumours expressed low molecular weight cytokeratin Ck18 in variable proportions of cells.
  • Even in monophasic tumours lacking obvious glandular differentiation in conventional staining, a number of neoplastic cells still expressed those cytokeratins.
  • Double immunofluorescence revealed tumour cells exclusively staining for Ck5/Ck14 in the presence of other cell populations that co-expressed high molecular weight Ck5/Ck14 as well as either low molecular weight Ck8/18 or SMA.
  • Based on morphology, we assigned the series to three categories, benign, borderline and malignant.
  • This classification was supported by a stepwise increase in cytogenetic alterations on CGH.
  • CONCLUSION: Adenomyoepithelial tumours comprise a spectrum of neoplasms consisting of an admixture of glandular and myoepithelial differentiation patterns.
  • Although categorisation of adenomyoepithelial tumours in benign, borderline and malignant was supported by results of CGH, any assessment of prognosis requires to be firmly based on morphological grounds.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Epithelial Cells / cytology. Myoepithelioma / diagnosis
  • [MeSH-minor] Actins / biosynthesis. Adult. Aged. Aged, 80 and over. Cell Proliferation. DNA-Binding Proteins. Female. Genes, Tumor Suppressor. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Immunophenotyping. Keratins / biosynthesis. Microscopy, Fluorescence. Middle Aged. Nucleic Acid Hybridization. Phosphoproteins / biosynthesis. Prognosis. Trans-Activators / biosynthesis. Transcription Factors. Tumor Suppressor Proteins. Vimentin / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1998 Feb;184(2):197-206 [9602712.001]
  • [Cites] Histopathology. 1997 Jun;30(6):542-8 [9205858.001]
  • [Cites] Exp Cell Res. 1999 Feb 25;247(1):267-78 [10047469.001]
  • [Cites] J Pathol. 1999 Dec;189(4):521-6 [10629552.001]
  • [Cites] Virchows Arch. 2000 Feb;436(2):158-66 [10755607.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):693-706 [11914275.001]
  • [Cites] Ultrastruct Pathol. 2002 Mar-Apr;26(2):77-80 [12036095.001]
  • [Cites] Lab Invest. 2002 Nov;82(11):1525-33 [12429812.001]
  • [Cites] J Pathol. 2002 Dec;198(4):458-67 [12434415.001]
  • [Cites] J Pathol. 2002 Dec;198(4):487-94 [12434418.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:33-44 [14521514.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:59-72 [14521516.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:73-84 [14521517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • [Cites] Semin Diagn Pathol. 2004 Feb;21(1):57-64 [15074560.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • [Cites] Exp Cell Res. 1991 Jun;194(2):267-74 [1709103.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2156-60 [8134364.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • (PMID = 16050957.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1187882
  •  go-up   go-down


47. Rubello D, Nanni C, Castellucci P, Rampin L, Farsad M, Franchi R, Mariani G, Menaldo G, Fanti S: Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses. Panminerva Med; 2005 Sep;47(3):187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The potential role of 18F-FDG PET/CT in distinguishing benign from malignant parotid masses in 14 consecutive patients was investigated.
  • At FDG PET/CT, 9 false positive cases were found (8 Warthin's tumours, 1 pleomorphic adenoma), 1 false negative (acinar cell carcinoma), 4 true negative (1 Warthin's tumour, 1 pleomorphic adenoma, 1 lymph epithelial cyst, 1 parotid inflammation) whereas there was no case of true positive.
  • CONCLUSIONS: In agreement with other preliminary reports in which the FDG PET without CT fusion imaging was used, in our experience 18F-FDG PET/CT did not prove to play a significant role in differential diagnosis (benign vs malignant) of parotid masses.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462726.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


48. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer; 2005 Jun 20;92(12):2171-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular proteases of the matrix metalloproteinase (MMP) and serine protease families participate in many aspects of tumour growth and metastasis.
  • Using quantitative real-time RT-PCR analysis, we have undertaken a comprehensive survey of the expression of these enzymes and of their natural inhibitors in 44 cases of human prostate cancer and 23 benign prostate specimens.
  • We found increased expression of MMP10, 15, 24, 25 and 26, urokinase plasminogen activator-receptor (uPAR) and plasminogen activator inhibitor-1 (PAI1), and the newly characterised serine proteases hepsin and matriptase-1 (MTSP1) in malignant tissue compared to benign prostate tissue.
  • The cellular localisation of the expression of the deregulated genes was evaluated using primary malignant epithelial and stromal cell cultures derived from radical prostatectomy specimens.
  • MMP10 and 25, hepsin, MTSP1 and maspin showed predominantly epithelial expression, whereas TIMP 3 and 4, RECK, MMP2 and 23, uPAR and PAI1 were produced primarily by stromal cells.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2002 Oct;42(4):398-406 [12361907.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):46845-8 [12384513.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6812-6 [12460890.001]
  • [Cites] Cancer Detect Prev. 2002;26(6):435-43 [12507228.001]
  • [Cites] J Urol. 2003 Mar;169(3):1157-61 [12576872.001]
  • [Cites] BJU Int. 2003 Mar;91(4):315-23; discussion 323-4 [12603403.001]
  • [Cites] J Urol. 2003 Apr;169(4):1316-9 [12629351.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):333-45 [12651907.001]
  • [Cites] Nat Med. 2003 Apr;9(4):407-15 [12652295.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):198-206 [15386409.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1090-6 [15564434.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55540-4 [15501821.001]
  • [Cites] Urol Res. 2005 Feb;33(1):44-50 [15517230.001]
  • [Cites] Prostate. 2000 Jan;42(1):18-25 [10579795.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):327-32 [10811500.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):879-82 [10854562.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36720-5 [10962009.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6927-34 [11156392.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2365-70 [11289097.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1301-11 [11290548.001]
  • [Cites] Expert Rev Mol Med. 2003 Sep;5(23):1-39 [14585170.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1196-201 [14652000.001]
  • [Cites] J Urol. 2004 Jan;171(1):187-91 [14665873.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3937-44 [14666700.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):463-70 [14735194.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):845-51 [14647437.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):590-8 [14744773.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2121-34 [12687014.001]
  • [Cites] Curr Top Dev Biol. 2003;54:263-312 [12696753.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15056-64 [12586837.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2292-9 [12727852.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):453-9 [12798711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7847-52 [12788977.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):382-7 [12845678.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1017-25 [12871983.001]
  • [Cites] Eur J Haematol. 2003 Aug;71(2):91-9 [12890147.001]
  • [Cites] Adv Exp Med Biol. 2003;532:91-107 [12908552.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):246-56 [12915116.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):217-22 [12970724.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40364-72 [12904305.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6758-62 [14583471.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9147-52 [9083044.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):246-58 [9174126.001]
  • [Cites] Oncogene. 1997 Jun 12;14(23):2767-74 [9190892.001]
  • [Cites] J Urol. 1998 Nov;160(5):1872-6 [9783977.001]
  • [Cites] J Clin Invest. 1998 Dec 1;102(11):2002-10 [9835626.001]
  • [Cites] Prostate. 1999 May;39(2):123-9 [10221568.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2570-6 [10363975.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2094-102 [10473092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11054-61 [10500122.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):952-61 [14871825.001]
  • [Cites] Prostate. 2004 May 1;59(2):167-76 [15042617.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):155-69 [15069676.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):185-95 [15324701.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):3605-11 [15356104.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):228-35 [15368474.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(2):144-50 [1848860.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4493-8 [7691397.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):585-91 [8129044.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):485-93 [11342332.001]
  • [Cites] Biochem J. 2001 Jun 15;356(Pt 3):705-18 [11389678.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):55-63 [11437402.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4337-43 [11466614.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] J Urol. 2001 Dec;166(6):2171-7 [11696729.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Blood. 2002 Jan 1;99(1):258-67 [11756180.001]
  • [Cites] Anal Biochem. 2002 Jan 15;300(2):269-73 [11779121.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1101-7 [11948120.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2169-80 [12057920.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):509-19 [12094217.001]
  • [Cites] J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 [12235282.001]
  • [Cites] Cancer Detect Prev. 2002;26(3):222-8 [12269770.001]
  • (PMID = 15928670.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RECK protein, human; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2361819
  •  go-up   go-down


49. Drieschner N, Kerschling S, Soller JT, Rippe V, Belge G, Bullerdiek J, Nimzyk R: A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. Gene; 2007 Nov 15;403(1-2):110-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • THADA, mapping to chromosomal band 2p21 is target gene of specific chromosomal rearrangements observed in thyroid benign tumors.
  • Thus, it is one of the most common gene targets in chromosomal rearrangements in benign epithelial tumors.
  • [MeSH-major] Adenoma / genetics. Chromosome Aberrations. Gene Rearrangement. Neoplasm Proteins / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889454.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


50. Furusato B, Shaheduzzaman S, Petrovics G, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, Srivastava S, Sesterhenn IA: Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer Prostatic Dis; 2008;11(2):194-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
  • Furthermore, to increase the sample quality, we utilized laser capture microdissection of prostate tumor and benign epithelial cells.
  • [MeSH-major] Adenocarcinoma / genetics. Epithelial Cells / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics. Prostate / metabolism. Prostatic Neoplasms / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Tissue Preservation / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768422.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


51. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS: Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest; 2005;60(2):75-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours.
  • This study analysed the biological relevance of E-cadherin, alpha-catenin, beta-catenin and gamma-catenin immunoexpression pattern (reduced vs. preserved phenotype) in epithelial ovarian tumours.
  • Immunohistochemistry was used to evaluate the expression of these proteins in 154 epithelial ovarian tumours, consisting of 17 benign, 33 borderline and 104 malignant tumours.
  • In borderline tumours, the immunoexpression pattern of E-cadherin (p = 0.014) and alpha-catenin (p = 0.030) associated with histological type.
  • In malignant tumours, the immunoexpression pattern of E-cadherin was related with histological type (p = 0.001).
  • The immunoexpression pattern of beta-catenin associated with histological type and tumour differentiation (p = 0.005, p = 0.025, respectively).
  • The preserved phenotype of E-cadherin was most frequently observed in mucinous tumours, whereas reduced E-cadherin was most frequently observed in serous tumours.
  • Although the reduced phenotype was the most frequent immunoexpression observed for all proteins of the E-cadherin-catenin complex in epithelial ovarian tumours, only beta-catenin showed a significant difference between benign, borderline and malignant tumours (p = 0.045), since borderline and malignant tumours most frequently showed the reduced phenotype.
  • The immunohistochemical profile of beta-catenin was shown to be of biological relevance: reduced beta-catenin was correlated with loss of tumour differentiation and serous carcinomas that are known to depict aggressive biological behaviour in epithelial ovarian tumours.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15785075.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Desmoplakins; 0 / JUP protein, human; 0 / Trans-Activators; 0 / alpha Catenin; 0 / beta Catenin; 0 / gamma Catenin
  •  go-up   go-down


52. Tokés AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res; 2005;7(2):R296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.
  • INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions.
  • CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours).
  • However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia.
  • CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene.
  • CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue.
  • [MeSH-major] Breast Diseases / genetics. Breast Neoplasms / genetics. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Claudin-1. Claudin-3. Claudin-4. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Tight Junctions

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cell Biol. 1999 Dec;78(12):849-55 [10669103.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48350-5 [11602598.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] J Cell Biol. 2002 Mar 18;156(6):1099-111 [11889141.001]
  • [Cites] J Cell Physiol. 2002 Apr;191(1):60-8 [11920682.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]
  • [Cites] Prog Biophys Mol Biol. 2003 Jan;81(1):1-44 [12475568.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Int J Mol Med. 2003 Jun;11(6):683-9 [12736707.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Jul;29(1):62-70 [12600828.001]
  • [Cites] Arch Androl. 2003 Jul-Aug;49(4):271-9 [12851029.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Sci. 1979 Feb;35:393-402 [422677.001]
  • [Cites] FEBS Lett. 1987 Sep 14;221(2):359-64 [3114004.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Cell Physiol. 1992 Jul;152(1):35-47 [1618921.001]
  • [Cites] J Cell Biol. 1998 Apr 20;141(2):397-408 [9548718.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1539-50 [9647647.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):391-401 [9786950.001]
  • [Cites] Gene. 1999 Jan 21;226(2):285-95 [9931503.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):268-73 [10370242.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1425-31 [10426787.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1035-8 [10508613.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):195-204 [10508866.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Hum Genet. 2000 Sep;107(3):249-56 [11071387.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):854-63 [11159859.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1319-27 [11375422.001]
  • [Cites] Clin Chem Lab Med. 2000 Feb;38(2):171-7 [10834406.001]
  • (PMID = 15743508.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1064136
  •  go-up   go-down


53. Van Effenterre R, Boch AL: [Craniopharyngiomas]. Ann Endocrinol (Paris); 2007 Dec;68(6):412-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are rare benign epithelial tumors, arising from the pituitary stalk or gland and developing in the sellar and suprasellar region, affecting both adults and children.
  • Diagnosis is made on MRI and CT scan, demonstrating a sellar or suprasellar tumor, heterogeneous, with frequent calcifications.
  • This classification allows surgical series comparison, which is of importance since developments and extensions of the tumor can explain surgical difficulties.
  • Because it is an extra-cerebral benign lesion, the ideal goal of treatment should be complete tumor removal with improvement of altered visual functions, minimal deterioration of endocrine function, and no neuropsychological impairment.
  • But the situation of the tumor, its relationship with third ventricle, hypothalamus, optic tract, vascular structures make its removal often difficult.
  • When total removal is impossible, radiotherapy may reduce the risk of a poor evolution.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825241.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 23
  •  go-up   go-down


54. Richter M, Meyer W, Küster J, Middel P: Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity. Diagn Pathol; 2010;5:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity.
  • BACKGROUND: Mixed epithelial and stromal tumour (MEST) represents a recently described benign composite neoplasm of the kidney, which predominantly affects perimenopausal females.
  • Most tumours are benign, although rare malignant cases have been observed.
  • Surgical exploration showed a tumour arising from the lower anterior hilus of the left kidney.
  • The tumour could be excised by preserving the kidney.
  • By intraoperative frozen section the tumour showed characteristic features of MEST with epithelial-covered cysts embedded in an "ovarian-like" stroma.
  • Additional immunohistochemistry investigations showed expression for hormone receptors by the stromal component of the tumour.
  • Commonly, the tumour arises from the renal parenchyma or pelvis.
  • The tumour is composed of an admixture of cystic and sometimes more solid areas.
  • CONCLUSION: MEST represents a distinctive benign tumour entity of the kidney, which affects perimenopausal woman.
  • The tumour should be distinguished from other cystic renal neoplasms.
  • By imaging studies it is difficult to distinguish between a benign or malignant nature of the tumour.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 2005 May-Aug;29(3-4):283-6 [16036882.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Pathology. 2007 Apr;39(2):235-40 [17454754.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):60-5 [17873894.001]
  • [Cites] Urology. 2008 Jun;71(6):1142-8 [18313107.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1237-46 [18006141.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1245-6 [18006142.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):72-80 [18971776.001]
  • [Cites] APMIS. 2008 Nov;116(11):1013-5 [19133001.001]
  • [Cites] Pathology. 2009;41(4):403-6 [19404861.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] J Urol. 2001 Oct;166(4):1381-2 [11547080.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Histopathology. 2004 Mar;44(3):302-4 [14987239.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):80-5 [16390243.001]
  • (PMID = 20193076.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2842239
  • [General-notes] NLM/ Original DateCompleted: 20100609
  •  go-up   go-down


55. Montironi R, Mazzucchelli R, Lopez-Beltran A, Martignoni G, Cheng L, Montorsi F, Scarpelli M: Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol; 2008 Dec;54(6):1237-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity?
  • OBJECTIVES: The term "renal epithelial and stromal tumour" (REST) was proposed recently to encompass the spectrum of findings observed in cystic nephroma (CN) and mixed epithelial and stromal tumour (MEST) of the kidney.
  • Our aim was to review the broad spectrum of usual and unusual clinical and morphologic findings observed in CN and MEST.
  • RESULTS: CN and MEST have a remarkable similarity in sex predilection, age distribution, and morphologic attributes of both the epithelial and stromal components and immunohistochemical profile, albeit with variation in individual categories, with higher prevalence of stromal-to-epithelial ratio, prominent ovarian-like stroma, smaller cysts, and stromal luteinisation in MEST, and large cysts, thin septa, and low stromal-to-epithelial ratio in CN.
  • Rare and unusual morphologic features, such as endometrioid, cervical, and intestinal differentiation, and luteinised ovarian-like stroma, have been described in MEST.
  • The epithelial element occasionally shows estrogen and progesterone receptors.
  • Even though an aggressive behaviour has been reported in very few cases, in general both neoplasms are considered benign and surgical excision is curative.
  • [MeSH-major] Kidney Neoplasms / classification. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cystic nephroma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2008 Dec;54(6):1245-6 [18006142.001]
  • [CommentIn] Eur Urol. 2009 Jul;56(1):e3 [19167806.001]
  • (PMID = 18006141.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 50
  •  go-up   go-down


61. Obulareddy SJ, Xin J, Truskinovsky AM, Anderson JK, Franklin MJ, Dudek AZ: Metanephric adenoma of the kidney: an unusual diagnostic challenge. Rare Tumors; 2010;2(2):e38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although metanephric adenoma (MA) is a rare, benign neoplasm of epithelial cells, it is often difficult to distinguish this entity from other malignant neoplasms preoperatively.
  • We report a case of a large renal mass for which preoperative diagnosis was indeterminate, with the differential diagnosis including Wilm's tumor, MA, and papillary renal cell carcinoma (PRCC).
  • Accurate postoperative differentiation of MA from PRCC is critical because adjuvant therapy is considered after surgical resection of PRCC tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139840.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994510
  • [Keywords] NOTNLM ; Wilm’s tumor / differential diagnosis. / metanephric adenoma / papillary renal cell carcinoma
  •  go-up   go-down


62. Bozza F, Marcelli VA, Pistilli R, Govoni FA, Marsico C: Maxillary ameloblastoma. Minerva Stomatol; 2006 Apr;55(4):215-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maxillary ameloblastoma is a rare odontogenic neoplasm that is histologically benign and originates from epithelial cells present in bone tissue.
  • If excised through conservative surgery, this tumour has a high relapse rate and is locally aggressive.
  • Thus, in these cases a complete and in-depth diagnostic work-up and careful planning of surgical treatment are needed: surgery entails an ablative phase with en-bloc resection of the neoformation to margins free of neoplastic infiltration, and a reconstruction phase that, within a short time-frame, will re-establish functionality and provide a good aesthetic result.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618996.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Hahne JC, Kummer S, Heukamp LC, Fuchs T, Gun M, Langer B, Von Ruecker A, Wernert N: Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1. Int J Oncol; 2009 Nov;35(5):989-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1.
  • Aberration in PTK signalling occurs in inflammatory diseases and diabetes, and aberrant expression can lead to benign proliferative conditions as well as to various forms of cancer.
  • Therefore, these enzymes are now used as targets in the treatment of different tumours.
  • Ets-1 is a transcription factor expressed in a number of human malignancies with demonstrated roles within both neoplastic cells and tumour stroma.
  • These roles include stimulation of tumour cell proliferation and invasion as well as tumour angiogenesis.
  • We investigated the role of Ets-1 in transcriptional regulation of a panel of 89 PTKs in epithelial HeLa tumour cells.
  • The data presented here underscore the importance of Ets-1 in tumour development and progression.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787252.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ETS1 protein, human; 0 / Proto-Oncogene Protein c-ets-1; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


64. Di Blasi A, Ferrara G, Antinolfi G, Dalena AM, Antinolfi F: [Clear cell adenomyoepithelioma of the ceruminous gland]. Pathologica; 2008 Jun;100(3):192-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ceruminous gland tumours are rare neoplasms.
  • We describe a case of a ceruminous tumour with complex morphology characterised by fibrous hyaline stroma bilayered epithelial ductal structures and nodules of tightly arranged clear cells with abundant Pas-positive cytoplasm.
  • Epithelial ductal basal cells were reactive for CK5, p63, calponin and SMA.
  • The lesion appears morphologically benign.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841827.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


65. Moriya T, Kozuka Y, Kanomata N, Tse GM, Tan PH: The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology; 2009 Jan;41(1):68-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It can be used to assist in distinguishing benign and malignant conditions, or to clarify the histological subtype of invasive carcinomas.
  • High molecular weight cytokeratins (CK5/6, CK14, 34betaE12) typically show a mosaic-like pattern of expression in benign papillary/hyperplastic lesions, and are mostly negative in ductal in situ carcinoma, but some exceptions exist.
  • Neuroendocrine differentiation (confirmed by anti-chromogranin A or synaptophysin) suggests malignancy in solid and papillary intraductal epithelial proliferations.
  • Cytokeratins, especially the antibody 34betaE12, are of value to differentiate spindle cell carcinoma from phyllodes tumour.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Immunohistochemistry / methods


66. Akhtar K, Khan N, Zaheer S, Sherwani R, Hasan A: Pindborg tumor in an adolescent. Oman Med J; 2010 Jan;25(1):47-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pindborg tumor in an adolescent.
  • Calcifying epithelial odontogenic tumor (Pindborg tumor), is a rare benign odontogenic neoplasm representing about 0.4-3% of all odontogenic tumors.
  • This tumor more frequently affects adults in the age range of 20-60 years, with a peak incidence in the 5th decade of life.
  • Calcifying epithelial odontogenic tumour has a much lower recurrence rate than ameloblastoma and malignant transformation, and metastasis is rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22125699.001).
  • [ISSN] 2070-5204
  • [Journal-full-title] Oman medical journal
  • [ISO-abbreviation] Oman Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3215391
  •  go-up   go-down


67. Ge MJ, Shi D, Wu QC, Wang M, Li LB: Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. J Cancer Res Clin Oncol; 2006 Apr;132(4):248-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period.
  • Additionally, the ten patients with benign lung disease served as control subjects undergoing surgical resection.
  • Surprisingly, circulating epithelial cells were detected in two patients resected for benign lung disease. (2) The CEA diagnostic test: the level of CEA mRNA ascended continuously within this period.
  • Both patients with benign lung disease served as control subjects undergoing surgical resection and the volunteers were negative.
  • CONCLUSIONS: A considerable proportion of patients who appear to have resectable NSCLC might be regarded as having systemic disease, which is often undetectable by current tumour staging method.
  • In terms of a marker used for the NSCLC patients who undergo operation, CEA is more suitable than CK19.
  • The CK19-expressing epithelial cells are released intraoperatively into the circulation, meanwhile CEA-expressing tumour cells are disseminated mostly postoperatively.
  • Surgical manipulation could promote the release of tumour cells into the bloodstream, but the ligation of pulmonary vein before the ligation of the pulmonary artery may partly prevent such release during surgery.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1999 Nov;126(5):820-6 [10568179.001]
  • [Cites] Biomol Eng. 2001 Mar;17(3):95-111 [11222984.001]
  • [Cites] Arch Surg. 1995 Apr;130(4):387-93 [7710337.001]
  • [Cites] Acta Oncol. 1991;30(6):668-75 [1659837.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6942-6 [10359818.001]
  • [Cites] Int J Cancer. 1997 Mar 17;70(6):674-8 [9096648.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2761-5 [9661888.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4021-7 [10632334.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24 [10393719.001]
  • [Cites] Clin Chem Lab Med. 2005;43(6):617-27 [16006258.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3388-93 [9363870.001]
  • [Cites] Int J Biol Markers. 1994 Apr-Jun;9(2):63-9 [7523543.001]
  • [Cites] Blood. 1991 Feb 15;77(4):874-8 [1993225.001]
  • [Cites] World J Surg Oncol. 2005 Mar 31;3(1):18 [15801980.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6836-40 [11156375.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 May;119(5):899-905 [10788810.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):94-9 [10763149.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):343-8 [9516921.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2562-71 [10561323.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):662-8 [16047189.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):8-13 [10719724.001]
  • (PMID = 16320073.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


68. Jordan S, Green A, Webb P: Benign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk? Cancer Causes Control; 2006 Jun;17(5):623-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk?
  • The natural history of the development of epithelial ovarian cancer remains obscure and no effective screening test exists.
  • In several human malignancies progression from benign to invasive tumour occurs, but this sequence has not been established for epithelial ovarian cancer.
  • We have reviewed epidemiological, histopathological and molecular studies of benign epithelial ovarian tumours to assess the evidence for and against such a progression in ovarian cancer.
  • These data suggest that a diagnosis of a benign ovarian cyst or tumour is associated with an increased risk of ovarian cancer later in life.
  • Current evidence also suggests that benign serous tumours can progress to low-grade serous cancer and that benign mucinous tumours can progress to mucinous cancer.
  • The more common high-grade serous ovarian cancers are likely to arise de novo.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / etiology. Ovarian Neoplasms / etiology. Precancerous Conditions / complications


69. Cordero Coma M, Yilmaz T, Foster CS: Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid. Acta Ophthalmol Scand; 2007 Nov;85(7):753-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid.
  • PURPOSE: The presence of tumour necrosis factor-alpha (TNF-alpha) in conjunctivae affected by ocular cicatricial pemphigoid (OCP) was investigated.
  • The expression of TNF-alpha was detected in both epithelial and stromal cells of conjunctivae from OCP patients.
  • [MeSH-major] Conjunctiva / metabolism. Conjunctivitis, Allergic / metabolism. Pemphigoid, Benign Mucous Membrane / metabolism. Tumor Necrosis Factor-alpha / metabolism


70. Ajura AJ, Sumairi I, Lau SH: The use of immunohistochemistry in an oral pathology laboratory. Malays J Pathol; 2007 Dec;29(2):101-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These cases ranged from benign to malignant lesions.
  • They include lymphomas (n=41), epithelial tumours (n=29), neural lesions (n=21), fibroblastic/myofibroblastic tumours (n=16), small round cell tumour (n=11), vascular tumours (n=4), smooth muscle tumours (n=4), myxomatous tumours (n=4) and skeletal muscle tumours (n=1).
  • [MeSH-major] Immunohistochemistry / utilization. Laboratories / standards. Mouth Diseases / diagnosis. Pathology, Clinical / standards

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108402.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


71. Uranues S, Alimoglu O, Todoric B, Toprak N, Auer T, Rondon L, Sauseng G, Pfeifer J: Laparoscopic resection of the pancreatic tail with splenic preservation. Am J Surg; 2006 Aug;192(2):257-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common indications are enucleation of endocrine-active tumors and distal resections for benign primary pancreatic lesions.
  • There were 4 cases of benign epithelial tumors of the pancreas and 1 case of a left-sided adrenal cyst, which pre- and intraoperatively gave the impression of a pancreatic cystadenoma.
  • No patient required blood transfusion, and there was only 1 postoperative fluid collection at the site of the tumor resection, which was drained percutaneously on the fourth postoperative day.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860642.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Pawlicki J, Król R, Kajor M, Ziaja J: [Case of malignant tumour phyllodes converting to fibrosarcoma]. Pol Merkur Lekarski; 2007 Mar;22(129):215-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant tumour phyllodes converting to fibrosarcoma].
  • Tumour phyllodes is rare breast neoplasm.
  • Tumours phyllodes are composed of hypercellular mesenchymal stroma and epithelial elements.
  • They are commonly classified as benign, rarely as borderline or malignant.
  • There is a case of large (28 x 24 cm) malignant tumour phyllodes presented in the article.
  • After surgical treatment of recurrent tumours (fibrosarcoma form) occurred two times during 1 year time.
  • In spite of unfavorable prognostic features of the tumour (large size, malignant histological character) and recurrences, final therapeutic effect was good.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Fibrosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Phyllodes Tumor / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682679.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


73. Münz M, Zeidler R, Gires O: The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett; 2005 Jul 8;225(1):151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP.
  • The epithelial cell adhesion molecule, EpCAM, is a transmembrane glycoprotein associated with both benign and malignant proliferation.
  • In cancer cells, expression levels of this tumour-associated antigen correlate positively with the grade of dysplasia and are also a negative prognostic factor for breast cancer patients.
  • De novo expression of EpCAM resulted in the rapid upregulation of the proto-oncogene c-Myc along with enhanced cell proliferation and metabolism.
  • Here, we analyzed the effects of EpCAM onto the proteome of epithelial cells.
  • Taken together, these results provide further evidence for the direct involvement of EpCAM in signalling processes, gene regulation, and cellular metabolism supporting its important role in tumour biology.
  • [MeSH-major] Antigens, Neoplasm / physiology. Carcinoma, Squamous Cell / genetics. Cell Adhesion Molecules / physiology. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Antigens, Differentiation. Carrier Proteins. Cell Proliferation. Epithelial Cells. Fatty Acid-Binding Proteins. Fatty Acids. Genes, myc. Humans. Proteome. Signal Transduction. Tumor Cells, Cultured. Up-Regulation

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922867.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / Carrier Proteins; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / FABP5 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / Fatty Acids; 0 / Proteome
  •  go-up   go-down


74. Sakai H, Mori T, Iida T, Tokuma Y, Maruo K, Masegi T: Immunohistochemical features of proliferative marker and basement membrane components of two feline inductive odontogenic tumours. J Feline Med Surg; 2008 Jul;10(3):296-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical features of proliferative marker and basement membrane components of two feline inductive odontogenic tumours.
  • Feline inductive odontogenic tumour (FIOT) is a rare and interesting odontogenic neoplasm in which the odontogenic epithelium has inductive potential to form aggregated foci of dental pulp-like mesenchymal cells.
  • Histopathologically, the masses consisted of non-encapsulated invasive neoplasms exhibiting proliferation of epithelial and mesenchymal components with local infiltration into the maxillary bone in both cases.
  • The epithelial component formed islands, anastomosing strands, and solid sheets of polygonal epithelial cells.
  • Type IV collagen and laminin were constantly positive around the foci of epithelial cells, and Ki-67 positive indices were extremely low; therefore, these findings consistent with the benign clinical presentation of FIOT.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / immunology. Mandibular Neoplasms / veterinary. Odontogenic Tumors / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766158.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type IV; 0 / Ki-67 Antigen
  •  go-up   go-down


75. Iezzi G, Piattelli A, Rubini C, Artese L, Fioroni M, Carinci F: MIB-1, Bcl-2 and p53 in odontogenic myxomas of the jaws. Acta Otorhinolaryngol Ital; 2007 Oct;27(5):237-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Odontogenic myxoma is a rare benign neoplasm occurring in the jaws.
  • In some cases (20%), odontogenic epithelial islands may be found.
  • The Authors evaluated p53, MIB-1, and Bcl-2 expressed by the epithelial and stromal elements in 12 cases of odontogenic myxoma of the jaws.
  • The cells of the odontogenic epithelium were positive for Bcl-2, p53 and MIB-1.
  • Proliferation of both the epithelial and stromal components could be related to the growth of this odontogenic tumour.
  • [MeSH-major] Genes, bcl-2 / genetics. Genes, p53 / genetics. Mandibular Neoplasms / genetics. Mandibular Neoplasms / pathology. Myxoma / genetics. Myxoma / pathology. Odontogenic Tumors / genetics. Odontogenic Tumors / pathology. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Humans. Middle Aged. Neoplasm Staging

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 2002 Aug;31(7):415-20 [12165060.001]
  • [Cites] Life Sci. 2003 Oct 17;73(22):2865-72 [14511771.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Dec;61(12):1463-6 [14663812.001]
  • [Cites] Oncol Res. 2005;15(5):249-55 [16261844.001]
  • [Cites] Int J Exp Pathol. 2005 Dec;86(6):375-81 [16309543.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4699-706 [16334163.001]
  • [Cites] J Clin Periodontol. 2006 Jan;33(1):76-8 [16367860.001]
  • [Cites] J Oral Pathol Med. 2006 Jul;35(6):369-75 [16762018.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Aug;35(8):750-5 [16690252.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Sep;64(9):1343-52 [16916667.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Jun;32(3):161-5 [15113574.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jun;33(4):333-7 [15145033.001]
  • [Cites] Oral Oncol. 2004 Oct;40(9):954-9 [15380175.001]
  • [Cites] J Clin Pathol. 1973 Aug;26(8):570-82 [4354841.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1975 Jun;39(6):901-17 [1055976.001]
  • [Cites] J Oral Pathol. 1977 Nov;6(6):343-58 [412928.001]
  • [Cites] J Oral Pathol. 1985 Apr;14(4):299-306 [3923172.001]
  • [Cites] J Maxillofac Surg. 1986 Feb;14(1):46-52 [3456413.001]
  • [Cites] J Oral Pathol Med. 1991 Mar;20(3):114-9 [2037972.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(5):377-83 [1375793.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):126-31 [7913362.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):138-41 [8032302.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):377-80 [7536506.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):419-23 [7719225.001]
  • [Cites] J Oral Maxillofac Surg. 1995 May;53(5):518-21 [7722719.001]
  • [Cites] Mod Pathol. 1995 Feb;8(2):150-4 [7777475.001]
  • [Cites] Histopathology. 1995 Mar;26(3):219-28 [7797199.001]
  • [Cites] J Oral Pathol Med. 1995 May;24(5):221-6 [7542341.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):759-62 [7560205.001]
  • [Cites] J Oral Pathol Med. 1995 Aug;24(7):313-5 [7473268.001]
  • [Cites] Int J Oral Maxillofac Surg. 1995 Jun;24(3):221-5 [7594756.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):102-10 [8617450.001]
  • [Cites] J Pathol. 1996 Apr;178(4):393-7 [8691316.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):143-9 [8762869.001]
  • [Cites] Cancer Lett. 1996 Aug 2;105(2):139-46 [8697436.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):380-3 [8746268.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):392-5 [8746270.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):403-4 [8746274.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Oct;82(4):426-33 [8899782.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Sep;32B(5):328-32 [8944836.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Nov;32B(6):394-400 [9039223.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):33-6 [9059353.001]
  • [Cites] Pathol Res Pract. 1997;193(1):1-7 [9112268.001]
  • [Cites] J Pathol. 1997 Aug;182(4):392-7 [9306959.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Dec;84(6):672-5 [9431538.001]
  • [Cites] Oral Oncol. 1997 Nov;33(6):419-25 [9509126.001]
  • [Cites] Pathol Res Pract. 1998;194(5):309-17 [9651943.001]
  • [Cites] J Pathol. 1998 Apr;184(4):360-8 [9664901.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):191-6 [9682980.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4415-7 [9891502.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):716-24 [10023332.001]
  • [Cites] Mol Pathol. 1998 Oct;51(5):254-61 [10193519.001]
  • [Cites] J Oral Pathol Med. 2005 Jan;34(1):46-52 [15610406.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Feb;99(2):191-5 [15660091.001]
  • [Cites] J Oral Pathol Med. 2005 May;34(5):257-62 [15817067.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):811-9 [15944979.001]
  • [Cites] Int Endod J. 2005 Jul;38(7):465-9 [15946267.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):432-5 [16053855.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2589-92 [16080498.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Oct;44(2):204-11 [16001434.001]
  • [Cites] J Oral Pathol Med. 2005 Nov;34(10):602-7 [16202080.001]
  • [Cites] Head Neck. 2005 Nov;27(11):982-9 [16136583.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1157-62 [16254104.001]
  • [Cites] Semin Diagn Pathol. 1999 Nov;16(4):297-301 [10587272.001]
  • [Cites] J Oral Pathol Med. 2000 Mar;29(3):129-38 [10738940.001]
  • [Cites] J Oral Pathol Med. 2000 Mar;29(3):139-44 [10738941.001]
  • [Cites] J Laryngol Otol. 2000 Jul;114(7):533-5 [10992937.001]
  • (PMID = 18198753.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2640038
  •  go-up   go-down


76. Inoguchi N, Matsumura Y, Kanazawa N, Morita K, Tachibana T, Sakurai T, Utani A, Miyachi Y: Expression of prostate-specific antigen and androgen receptor in extramammary Paget's disease and carcinoma. Clin Exp Dermatol; 2007 Jan;32(1):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate-specific antigen (PSA) is a kallikrein-like serine proteinase (human kallikrein 3) produced by epithelial cells of both benign and malignant prostate tissue.
  • Tumour cells positive for PSA were found in 17 of the 34 cases.


77. Groisman GM, Polak-Charcon S, Appelman HD: Fibroblastic polyp of the colon: clinicopathological analysis of 10 cases with emphasis on its common association with serrated crypts. Histopathology; 2006 Mar;48(4):431-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemically, all cases were positive for vimentin and negative for desmin, smooth-muscle actin, h-caldesmon, S100 protein, c-Kit, epithelial membrane antigen, cytokeratin AE1/3, CD34, CD68, COX-2, and factor XIIIa.
  • Ultrastructural examination supported the fibroblastic nature of the tumour cells.
  • CONCLUSIONS: FP is a distinctive type of benign mucosal colorectal polyp characterized by its distal location, small size, frequent association with hyperplastic polyps, distinct morphological appearance and typical immunonegativity for markers of specific differentiation.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487365.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


78. Engers R, Mueller M, Walter A, Collard JG, Willers R, Gabbert HE: Prognostic relevance of Tiam1 protein expression in prostate carcinomas. Br J Cancer; 2006 Oct 23;95(8):1081-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Rac-specific guanine nucleotide exchange factor, Tiam1, plays a major role in oncogenicity, tumour invasion and metastasis but its usefulness as a prognostic marker in human cancer has not been tested yet.
  • In the present study, Tiam1 expression was analysed in benign secretory epithelium, pre-neoplastic high-grade prostatic intraepithelium neoplasia (HG-PIN) and prostate carcinomas of 60 R0-resected radical prostatectomy specimens by semiquantitative immunohistochemistry.
  • Tiam1 proved significantly overexpressed in both HG-PIN (P<0.001) and prostate carcinomas (P<0.001) when compared to benign secretory epithelium.
  • > or =3.5-fold) in prostate carcinomas relative to the respective benign prostatic epithelium was statistically significantly associated with disease recurrence (P=0.016), the presence of lymph vessel invasion (P=0.031) and high Gleason scores (GS) (i.e.
  • Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28443-50 [11328805.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):867-71 [12075356.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):21-32 [14999151.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100 [15298146.001]
  • [Cites] NCI Monogr. 1988;(7):15-8 [3173500.001]
  • [Cites] Cell. 1994 May 20;77(4):537-49 [7999144.001]
  • [Cites] Gynecol Oncol. 1994 May;53(2):220-7 [8188083.001]
  • [Cites] Nature. 1995 Mar 30;374(6521):457-9 [7700355.001]
  • [Cites] Nature. 1995 May 25;375(6529):338-40 [7753201.001]
  • [Cites] Cell. 1995 Jun 30;81(7):1137-46 [7600581.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):23934-6 [7592586.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2215-21 [8570171.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3707-13 [8668187.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):286-92 [8772781.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] Nature. 1997 Dec 11;390(6660):632-6 [9403696.001]
  • [Cites] J Cell Biol. 1998 Nov 30;143(5):1385-98 [9832565.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):543-8 [16249175.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):369-76 [11054665.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):167-73 [11322835.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41889-97 [11551917.001]
  • (PMID = 17003780.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / TIAM1 protein, human
  • [Other-IDs] NLM/ PMC2360703
  •  go-up   go-down


79. Kayastha S: Study of ovarian tumours in Nepal Medical College Teaching Hospital. Nepal Med Coll J; 2009 Sep;11(3):200-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of ovarian tumours in Nepal Medical College Teaching Hospital.
  • This was a retrospective study of all the cases of ovarian tumours operated in Nepal Medical College Teaching Hospital from January 2006 to July 2008.
  • All the cases of ovarian tumour were included, irrespective of whether diagnosed preoperatively or found incidently during operation.
  • The nature of tumour whether benign or malignant, their presenting symptoms, age, parity age of menarche, type of operation and histopathological finding was recorded.
  • The incidence of ovarian tumour was 16.7% among total gynaecological admissions, out of which malignant ovarian tumour was 9.5%.
  • Benign tumour occurred in all age group 86 (90.5%) while maximum of malignant tumour occurred after 40 years (66.7%).
  • Seventy two point six percent were surface epithelium tumour which is common in older women.
  • Twenty seven percent were germ cell tumour which is common in younger age group.
  • Commonest surface epithelial tumour was serous cyst adenoma (40.0%) and commonest germ cell tumour was Dermoid (25.3%).Commonest complication of ovarian cyst was torsion (12.6%).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20334071.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


80. Pastor T, Popović B, Gvozdenović A, Boro A, Petrović B, Novaković I, Puzović D, Luković L, Milasin J: [Alterations of c-Myc and c-erbB-2 genes in ovarian tumours]. Srp Arh Celok Lek; 2009 Jan-Feb;137(1-2):47-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alterations of c-Myc and c-erbB-2 genes in ovarian tumours].
  • This cancer results from a succession of genetic alterations involving oncogenes and tumour suppressor genes, which have a critical role in normal cell growth regulation.
  • Mutations and/or overexpression of three oncogenes, c-erbB-2, c-Myc and K-ras, and of the tumour suppressor gene p53, have been frequently observed in a sporadic ovarian cancer.
  • METHODS: DNA was isolated from 15 samples of malignant and 5 benign ovarian tumours, using proteinase K digestion, followed by phenol-chloroform isoamyl extraction and ethanol precipitation.
  • RESULTS: The amplification of both c-Myc and c-erbB-2 was detected in 26.7% of ovarian epithelial carcinoma specimens.
  • Only one tumour specimen concomitantly showed increased gene copy number for both studied genes.
  • CONCLUSION: The amplification of c-Myc and c-erbB-2 oncogenes in ovarian epithelial carcinomas is most probably a late event in the pathogenesis conferring these tumours a more aggressive biological behaviour.
  • Similarly, gene deletions point to genomic instability in epithelial carcinomas in higher clinical stages as the result of clonal evolution and selection.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Gene Deletion. Genes, ras. Humans. Middle Aged. Polymerase Chain Reaction. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370966.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


81. O'Hurley G, O'Grady A, Smyth P, Byrne J, O'Leary JJ, Sheils O, William R, Watson G, Kay EW: Evaluation of Zinc-α-2-Glycoprotein and Proteasome Subunit β-Type 6 Expression in Prostate Cancer Using Tissue Microarray Technology. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):512-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Zinc-α-2-glycoprotein (ZAG) and proteasome subunit β-Type 6 (PSMB-6) were found to be up-regulated in the serum of CaP patients with higher grade tumors after 2-dimensional difference gel electrophoresis analysis.
  • The aim of this study was to investigate if ZAG and PSMB-6 were also overexpressed in prostatic tumor tissue of CaP patients.
  • ZAG expression in CaP epithelial cells was inversely associated with Gleason grade (benign prostatic hyperplasia>G3>G4/G5).
  • PSMB-6 was not expressed in either tumor or benign epithelium.
  • [MeSH-minor] Adult. Aged. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Grading. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Lippincott Williams & Wilkins, Inc.
  • (PMID = 20661134.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Seminal Plasma Proteins; 0 / Zn-alpha-2-glycoprotein; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


82. Zhang J, Jianmin, Wang N, Shi J, Ge X: A case of primary oncocytic adenocarcinoma of the lacrimal sac. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lacrimal sac tumours are rare entities.
  • Neoplasms of the lacrimal system may conveniently be grouped into epithelial and non-epithelial types: papillomas are the most common benign epithelial tumours, while oncocytic adenocarcinomas are extremely rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orbit. 2005 Dec;24(4):291-3 [16354642.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):476-90 [7413136.001]
  • [Cites] Ear Nose Throat J. 1995 Oct;74(10):717-20 [8529551.001]
  • [Cites] Ophthalmic Surg. 1995 Jul-Aug;26(4):377-9 [8532297.001]
  • [Cites] Arch Ophthalmol. 1978 Feb;96(2):303-4 [629677.001]
  • (PMID = 21747898.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029480
  •  go-up   go-down


83. Kabasawa Y, Nagumo K, Takeda Y, Kawashima N, Okada N, Omura K, Yamaguchi A, Katsube K: Amelogenin positive cells scattered in the interstitial component of odontogenic fibromas. J Clin Pathol; 2008 Jul;61(7):851-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Odontogenic tumours are often biphasic, consisting of epithelial and interstitial components, with an origin that is not well understood.
  • Odontogenic fibromas are rich in mesenchymal component, but also have many epithelial nests.
  • AIMS: To investigate the origin of this tumour by immunohistochemistry.
  • METHODS: The expression of several odontogenic and epithelial markers, including amelogenin, was investigated by immunofluorescent studies.
  • RESULTS: Immunohistochemical analysis showed that epithelial nests exhibited E-cadherin expression, but not amelogenin.
  • Amelogenin positive cells were scattered in the fibrous tissue, which did not exhibit epithelial marker expression except for epithelial membrane antigen.
  • In one case that had received a test biopsy before whole resection of tumour, amelogenin positive cells were distributed in the regenerating mucosal epithelium or subepithelial tissue.
  • CONCLUSIONS: Results indicate that amelogenin positive cells of odontogenic fibromas have an epithelial origin and may have the potential for epithelial mesenchymal transition, which has not to date been investigated in benign tumours.
  • [MeSH-major] Amelogenin / metabolism. Biomarkers, Tumor / metabolism. Odontogenic Tumors / metabolism
  • [MeSH-minor] Adult. Cadherins / metabolism. Female. Humans. Male. Mandibular Neoplasms / metabolism. Mandibular Neoplasms / pathology. Maxillary Neoplasms / metabolism. Maxillary Neoplasms / pathology. Middle Aged. Neoplasm Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344235.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amelogenin; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Neoplasm Proteins
  •  go-up   go-down


84. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G: Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology; 2010 Apr;56(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.
  • AIMS: To study the relevance of periostin, known to be involved in epithelial-mesenchymal transition (EMT), in hepatocellular and bile duct cancer.
  • Normal bile ducts, gallbladder epithelium and hepatocytes showed weak cytoplasmic periostin expression.
  • In HCC, there was strong epithelial periostin expression in 19/91 (20.9%) and strong stromal periostin expression in 10/91 cases (11%).
  • Epithelial expression in tumour cells was significantly associated with a higher tumour grade (P < 0.05) and hepatitis B virus infection (P = 0.007).
  • Importantly, there was no strong periostin expression in benign liver tumours.
  • Strong stromal periostin expression was detected in 78/116 (67.2%) BDC and strong epithelial expression in 39/116 (33.6%) BDC. pT stage, differentiation grade and proliferation rate in primary BDC were independent of periostin expression.
  • Epithelial periostin expression was associated with reduced overall survival on univariate and multivariate analysis.
  • CONCLUSIONS: The EMT protein periostin is expressed in the stroma and epithelium of a subset of BDC and HCC.
  • Epithelial periostin expression is a marker for malignant transformation of hepatocytes and a novel prognostic marker in BDC.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459570.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  •  go-up   go-down


85. Avoranta T, Sundström J, Korkeila E, Syrjänen K, Pyrhönen S, Laine J: The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch; 2010 Dec;457(6):659-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
  • The aim of this study was to examine the distribution and expression of IIA PLA2 protein in benign, premalignant and malignant colorectal tumours as well as in peritumoural mucosa.
  • A total of 79% of adenomas and 31% of carcinomas showed IIA PLA2-immunopositive tumour cells in IHC, and the expression was localised to epithelial cells with ISH.
  • The epithelial cells in the peritumoural mucosa showed immunopositivity for IIA PLA2 in 96% of cases, with considerably stronger intensity adjacent to carcinoma than in the more distal mucosa.
  • Moreover, IIA PLA2-immunopositive malignant epithelial cells were found in 44% of cases in the invasive front of carcinomas.
  • Our results suggest that the IIA PLA2 protein content is dramatically decreased in malignant colorectal tumours as compared with adenomas.
  • [MeSH-minor] Aged. Aged, 80 and over. Apoptosis. Biopsy. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Male. Middle Aged. Necrosis. RNA, Messenger / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Inflammation. 1993 Aug;17 (4):453-64 [8406689.001]
  • [Cites] Cell. 1995 Jun 16;81(6):957-66 [7781071.001]
  • [Cites] Front Biosci. 2008 May 01;13:4144-74 [18508504.001]
  • [Cites] J Carcinog. 2009;8:5 [19332896.001]
  • [Cites] J Biochem. 1992 Sep;112(3):350-4 [1429522.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12 ):7402-8 [10358193.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):212-20 [15475936.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):377-86 [19136477.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16203-8 [12456890.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):130-6 [12591965.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12 ):3857-61 [11751475.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2636-43 [15805260.001]
  • [Cites] Ann Oncol. 2009 Jul;20(7):1230-5 [19276398.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98 (7):3935-9 [11274413.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7232-5 [1977517.001]
  • [Cites] Nat Genet. 1997 Sep;17 (1):88-91 [9288104.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12 ):1767-72 [12085323.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5184-6 [7585570.001]
  • [Cites] Drug Discov Today. 2003 Aug 1;8(15):710-6 [12927514.001]
  • [Cites] Mol Carcinog. 2007 Feb;46(2):106-16 [17091473.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):713-20 [10086656.001]
  • [Cites] Oncogene. 1998 Oct 15;17 (15):2009-12 [9788445.001]
  • [Cites] Clin Chem. 1992 Sep;38(9):1824-9 [1526020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):500-3 [9458096.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):255-63 [16458424.001]
  • [Cites] Adv Exp Med Biol. 1990;275:17-34 [2239445.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1084-91 [10706128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11280-5 [11005842.001]
  • [Cites] Clin Infect Dis. 1993 Nov;17 (5):864-70 [8286627.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):545-8 [11520087.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92 (2):289-92 [9040208.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3182-92 [10918573.001]
  • [Cites] J Rheumatol. 1993 Feb;20(2):325-30 [8474071.001]
  • [Cites] APMIS. 2009 Mar;117(3):151-61 [19245588.001]
  • [Cites] Cell. 1993 Nov 19;75(4):631-9 [8242739.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2009 Jul-Aug;57(4):291-4 [19578817.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):667-71 [11839587.001]
  • [Cites] Gut. 1997 Jan;40(1):95-101 [9155583.001]
  • [Cites] Biochim Biophys Acta. 1998 May 27;1403(1):47-56 [9622592.001]
  • [Cites] Biochim Biophys Acta. 2005 Apr 15;1733(2-3):210-23 [15863368.001]
  • [Cites] Lab Invest. 1995 Feb;72 (2):201-8 [7853853.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5A):3179-85 [17970059.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5898-906 [20014453.001]
  • [Cites] Gut. 1994 Nov;35(11):1593-8 [7828979.001]
  • [Cites] APMIS. 1998 Aug;106(8):780-4 [9744764.001]
  • (PMID = 20938784.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.1.1.4 / Group II Phospholipases A2
  •  go-up   go-down


86. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer; 2005 Feb;41(3):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we analysed the expression of gelsolin in 241 matched cDNA pairs from human normal and tumour tissues using a Cancer Profiling Array.
  • On a protein level, we examined the expression of gelsolin in human ovarian cancer cell lines and in a set of 110 cases of human benign and malignant ovarian tumours.
  • Low levels of gelsolin protein were observed in four of six ovarian carcinoma cell lines, in contrast to its expression in normal ovarian surface epithelial cells.
  • In addition, we found a reduced expression of gelsolin in borderline tumours and ovarian carcinomas compared with the epithelium of normal ovaries and benign adenomas.
  • Re-expression of gelsolin in OAW42 and ES-2 cells resulted in a suppression of tumour cell survival in vitro.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Down-Regulation. Female. Humans. Immunohistochemistry. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691647.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gelsolin
  •  go-up   go-down


87. Tun K, Celikmez RC, Okutan O, Gurcan O, Beskonakli E: Dermoid tumour of the lateral wall of the cavernous sinus. J Clin Neurosci; 2008 Jul;15(7):820-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoid tumour of the lateral wall of the cavernous sinus.
  • Congenital intracranial dermoid tumors are very rare.
  • Dermoid tumors originating from the cavernous sinus are usually interdural and thus, presentation with ophthalmoplegia is uncommon.
  • They are congenital benign tumors and are believed to originate from ectopic inclusion of epithelial cells during closure of the neural tube during embryonic development.
  • In this report, we describe the case of a dermoid cyst that was embedded in the lateral wall of the cavernous sinus and review the literature relating to related cavernous dermoid lesions.
  • [MeSH-minor] Adult. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Dura Mater / pathology. Dura Mater / surgery. Female. Headache / etiology. Headache / pathology. Headache / physiopathology. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Oculomotor Nerve Diseases / etiology. Oculomotor Nerve Diseases / pathology. Oculomotor Nerve Diseases / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Neurosci. 2009 Aug;16(8):1115
  • (PMID = 18462942.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


88. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours.
  • In the present study we analysed the expression of this molecule in salivary gland tumours.
  • Archival formalin-fixed, paraffin-embedded sections of 40 benign and 57 malignant salivary gland tumours were retrieved and retrospectively studied immunohistochemically using a polyclonal C-KIT antibody in an Envision/HRP technique.
  • In addition five samples of chronic submandibular sialadenitis, five normal minor salivary glands and parotid or submandibular gland tissue adjacent to benign tumour were also studied.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.
  • Furthermore its expression in serous acinar cells in sialadenitis and intercalated ductal cells in normal and inflammatory lesions may indicate a possible participation in pathogenesis of both neoplastic and non-neoplastic salivary gland diseases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis. Salivary Gland Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


89. Guo DH, Pang SJ, Shen Y: [Atypical endometriosis: a clinicopathologic study of 163 cases]. Zhonghua Fu Chan Ke Za Zhi; 2008 Nov;43(11):831-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathologic features of atypical endometriosis (AEM) and to discuss the relationship between AEM and tumors.
  • The pathologic changes of AEM including its glandular epithelium, stroma, background and the conditions coexisting with tumor were observed.
  • AEM associated with tumour was found in 26 cases (15.95%) and among 27 of ovarian AEM, 15 were malignant, 9 borderline and 3 benign.
  • The AEM epithelia were mainly arranged in the form of surface epithelium.
  • They present with characteristic features of moderate to marked pleomorphism, epithelial tufting and bud structures by microscopy.
  • The walls of AEM cyst were presented with three layers of epithelium, endometrioid stroma and fibrosis-collagen.
  • The transformation from AEM to tumor was found in most of the malignant tumors (14/15, 93%).
  • CONCLUSIONS: AEM lesions hold some features of both EM and tumor, which may have a relatively higher potential for tumorigenesis and canceration.
  • The process of damage and repair in EM foci during a long course may play a role in the development of EM into AEM and finally into tumor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometriosis / pathology. Epithelium / pathology. Ovarian Neoplasms / pathology


90. Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G: Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer; 2010;10:273
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far.
  • Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign prostatic tissues (n = 38) were also analyzed.
  • RESULTS: In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and in 11 of 38 benign prostate glands (28.9%).
  • Increased periostin expression in carcinoma cells was significantly associated with high Gleason score (p < 0.01) and advanced tumour stage (p < 0.05) in the test cohort.
  • Whereas periostin expression was weak or absent in the stroma around normal prostate glands, strong periostin expression in tumour stroma was found in most primary and metastatic prostate cancers.
  • CONCLUSIONS: Our data indicate that periostin up-regulation is related to increased tumour aggressiveness in prostate cancer and might be a promising target for therapeutical interventions in primary and metastatic prostate cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Prostatic Neoplasms / chemistry
  • [MeSH-minor] Aged. Chi-Square Distribution. Cohort Studies. Epithelial Cells / chemistry. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / analysis. Stromal Cells / chemistry. Time Factors. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2002;86(4):792-804 [12210745.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):183-8 [11335131.001]
  • [Cites] Jpn J Cancer Res. 2001 Aug;92(8):869-73 [11509119.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] Cancer Lett. 2001 Oct 22;172(1):37-42 [11595127.001]
  • [Cites] J Pediatr Surg. 2002 Sep;37(9):1293-7 [12194119.001]
  • [Cites] Cell Tissue Res. 2003 Jun;312(3):345-51 [12761672.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):754-9 [12874078.001]
  • [Cites] Dev Dyn. 2004 Apr;229(4):857-68 [15042709.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] J Orthop Res. 2004 May;22(3):520-5 [15099630.001]
  • [Cites] J Appl Physiol (1985). 2004 Oct;97(4):1550-8; discussion 1549 [15121739.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):271-8 [8363580.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):77-83 [15514205.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2005 Dec;287(2):1205-12 [16240445.001]
  • [Cites] Thyroid. 2006 Feb;16(2):161-75 [16676402.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19700-8 [16702213.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2083-91 [16861259.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1396-403 [17060937.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(1):83-93 [16807673.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] Histol Histopathol. 2007 Oct;22(10):1167-74 [17616943.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] World J Gastroenterol. 2007 Oct 21;13(39):5261-6 [17876898.001]
  • [Cites] Int J Urol. 2007 Nov;14(11):1034-9 [17956532.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):604-10 [18212746.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):295-303 [18208976.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):494-8 [17938160.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2479-88 [18381457.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2707-18 [18381746.001]
  • [Cites] Cancer. 2008 Apr 25;114(2):124-33 [18327805.001]
  • [Cites] J Endocrinol. 2008 May;197(2):401-8 [18434370.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1425-35 [18403754.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):753-64 [18443362.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] Eur Urol. 2008 Nov;54(5):1097-106 [18061337.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7430-7 [19010860.001]
  • [Cites] Prostate. 2009 Sep 15;69(13):1398-403 [19479898.001]
  • [Cites] Histopathology. 2010 Apr;56(5):600-6 [20459570.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • (PMID = 20534149.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2903527
  •  go-up   go-down


91. Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE: Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer; 2006 Mar 1;118(5):1325-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of morphological subtypes are recognised (e.g. serous, mucinous, endometrioid), which may be benign, borderline or malignant.
  • Perturbed patterns of expression of the SEPT9 gene on chromosome 17q25.3 have been implicated in a variety of tumour types including both breast and ovarian neoplasia.
  • In preliminary studies, we showed that SEPT9 mRNA was upregulated in a bank of ovarian tumours, which included benign, borderline and malignant tumours, and reported increased levels of one splice variant, SEPT9_v4*.
  • We now describe a comprehensive analysis of SEPT9 expression specifically in serous and mucinous ovarian tumours (benign, borderline and malignant), using cDNA microarray, semi- and quantitative RTPCR of microdissected archival tumour material.
  • Our data show consistent and specific overexpression of both SEPT9_v1 and SEPT9_v4* transcripts in the epithelial component of ovarian tumours.
  • These transcripts show highest levels of expression in serous and mucinous borderline tumours.
  • Interestingly, highest levels of expression are observed in serous borderline and low-grade tumours rather than high-grade in keeping with a model of progression of benign, borderline and low-grade serous tumours.

  • Genetics Home Reference. consumer health - SEPT9 gene.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161048.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.1.- / SEPT9 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


92. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


93. Cardillo MR, Ippoliti F: Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol; 2007 Jan-Mar;20(1):37-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma.
  • Cytokines, notably the interleukins IL-6 and IL-10, have an important role in the development and progression of renal-cell carcinomas, acting in the host-tumor interaction and in tumor bulk.
  • Heat shock proteins (HSP), in particular HSP-90, may have a regulatory role in cytokine biosynthesis and prognostic implication in some tumors.
  • IL-6, IL-10 and HSP-90 proteins were more strongly expressed in epithelium and stroma of the renal tumoral compartment than in adjacent normal peritumoral tissue.
  • The percentage of cells expressing IL-6, IL-10 and HSP-90 immunoreactivity was higher in benign epithelial tumors, than in normal peritumoral tissue, but lower than in renal-cell carcinomas.
  • Whereas HSP-90 immunoreactivity seemed higher in more aggressive histological phenotypes (collecting-duct carcinoma) of renal-cell carcinomas, IL-10 protein levels were higher in more advanced TNM stage (pT3) tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346426.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


94. Friedrich RE, Li L, Knop J, Giese M, Schmelzle R: Pleomorphic adenoma of the salivary glands: analysis of 94 patients. Anticancer Res; 2005 May-Jun;25(3A):1703-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenoma is a benign epithelial tumor of adenoid structure preferentially arising from the parotid gland.
  • It was shown that complete tumor excision is a curative measure and recurrence is likely in incompletely excised tumors.
  • The aim of this study was to analyse the outcome of patients with pleomorphic adenoma from salivary glands in order to evaluate the surgical strategy of a single institution.
  • The tumor occurred more often in females than in males (45:28, parotid).
  • CONCLUSION: Pleomorphic adenoma from salivary glands is a benign tumor.
  • However, in a noteworthy number of patients, inside the benign tumor a phenotype develops with distinct properties of malignancy.
  • Multinodular tumors are prone to recurrent disease.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033086.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


95. Kamat G, Yelikar B, Shettar S, Karigoudar MH: Pigmented trichoblastoma with sebaceous hyperplasia. Indian J Dermatol Venereol Leprol; 2009 Sep-Oct;75(5):506-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trichoblastoma is a rare benign trichogenic tumour with epithelial and mesenchymal components recapitulating the germinal hair bulb and associated mesenchyme.
  • Microscopy of tumour revealed nodular tumour spanning the entire dermis with collection of mesenchymal cells resembling follicular papilla.
  • There is a need for differentiation of this tumor which is benign, from other pigmented tumors having basaloid arrangement of cells such as basal cell carcinoma.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / diagnosis. Sebaceous Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736433.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


96. Ishida M, Hotta M, Tsukamura A, Taga T, Kato H, Ohta S, Takeuchi Y, Nakasu S, Okabe H: Malignant transformation in craniopharyngioma after radiation therapy: a case report and review of the literature. Clin Neuropathol; 2010 Jan-Feb;29(1):2-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Craniopharyngioma is a benign epithelial tumor that is thought to arise from the remnant of the Rathke pouch.
  • MATERIALS AND METHODS: Histopathological and immunohistochemical analyses were carried out for specimens of the suprasellar tumor (from three resections, with the third surgery performed after radiation therapy).
  • RESULTS: The resected tumors from the first and second surgeries comprised islands of loosely cohesive aggregates of epithelial cells, so-called stellate reticulum.
  • At the periphery of the nests, palisaded columnar epithelium was observed.
  • Immunohistochemical studies revealed that the p53 protein was over-expressed in the malignant component, whereas its expression was much lower in the benign component.


97. Zhou L, Luo L, Hui X, Chen H, Yu B, Guo G, You C: Primary Rathke's cleft cyst in the cerebellopontine angle associated with apoplexy. Childs Nerv Syst; 2010 Dec;26(12):1813-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rathke's cleft cyst (RCC) is a congenital, benign, epithelial tumor and mainly occurs in sellar region and occasionally in suprasellar region; ectopic RCC is exceedingly rare.
  • The patient underwent the total tumor removal via the retrosigmoid approach with a good recovery.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2005;56(1):124-8; discussion 129 [15617594.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Feb;64(2):184-8 [16430718.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):535-44 [2002366.001]
  • [Cites] J Neurosurg. 2004 Oct;101(4):571-2; discussion 572 [15481706.001]
  • [Cites] Ear Nose Throat J. 1998 May;77(5):396-9, 403 [9615520.001]
  • [Cites] Surg Neurol. 1995 Jul;44(1):19-26; discussion 26-7 [7482247.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Mar;21(3):485-8 [10730639.001]
  • [Cites] J Neurosurg. 2005 Aug;103(2):389-90; author reply 390 [16175873.001]
  • [Cites] J Clin Neurosci. 2009 Mar;16(3):385-9 [19147363.001]
  • [Cites] J Endocrinol Invest. 2004 Nov;27(10):943-8 [15762042.001]
  • [Cites] Childs Nerv Syst. 1998 Jul;14(7):343-7 [9726587.001]
  • [Cites] J Neurosurg. 2008 Jan;108(1):3-8 [18173304.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):189-93 [15739543.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1836-9 [12368625.001]
  • (PMID = 20717684.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


98. Kamil ZS, Tong LC, Habeeb AA, Ghazarian D: Non-melanocytic mimics of melanoma: part I: intraepidermal mimics. J Clin Pathol; 2009 Feb;62(2):120-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma comprises a wide range of cytological and architectural features histopathologically and hence can mimic many benign and malignant lesions of epithelial, mesenchymal and hematopoietic cell lines of differentiation.
  • In this review, the different features of the benign, pre-malignant and malignant intraepidermal non-melanocytic tumours and tumour-like lesions that can closely mimic intraepidermal melanoma (melanoma in situ) are emphasised.
  • [MeSH-minor] Diagnosis, Differential. Humans. Keratosis / pathology. Precancerous Conditions / pathology. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930985.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 40
  •  go-up   go-down


99. Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S: Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol; 2005 Dec;86(6):397-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using several techniques, we have assessed morphological characteristics of a malignant thymic tumour in SV12 transgenic (Tg) mice expressing SV40 T and t antigens under control of an L-PK promoter.
  • We describe the development of a carcinoma originating from thymic hyperplasia and followed by the formation of a benign tumour composed chiefly of medullary epithelial cells expressing the transgene and of lymphocytes, a pathology very rarely reported in mice.
  • Our study of the SV12 Tg mice represents the first description of a model of a pure malignant thymic tumour associated with extensive angiogenesis maintained in numerous descendants.
  • The formation of a large tumoral neovascular network, observed here, has never been described in human and/or experimental thymic tumours.
  • The subset of different molecular weight CK components and their modifications are also considered, as well as the presence of type IV epithelial cells, progenitors of medullary epithelial cells.
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Antigens, Viral, Tumor / genetics. Neovascularization, Pathologic. Promoter Regions, Genetic. Pyruvate Kinase / genetics. Thymus Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Immunohistochemistry / methods. Male. Mice. Mice, Inbred CBA. Mice, Transgenic. Microscopy, Immunoelectron. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thymus. 1993 Aug;22(1):13-33 [7508157.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3979-83 [8171023.001]
  • [Cites] Prog Growth Factor Res. 1994;5(1):89-97 [7515293.001]
  • [Cites] Histopathology. 1994 Jul;25(1):21-9 [7959642.001]
  • [Cites] Int Rev Cytol. 1995;159:113-60 [7537724.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):127-37 [8534862.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] J Pathol. 1995 Nov;177(3):309-15 [8551394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5742-6 [8650163.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):263-77 [8821090.001]
  • [Cites] Cancer Lett. 1996 Oct 22;107(2):293-300 [8947527.001]
  • [Cites] Cell. 1997 Jun 13;89(6):981-90 [9200616.001]
  • [Cites] Science. 1997 Jul 4;277(5322):48-50 [9229772.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Lab Invest. 1990 Jun;62(6):690-6 [1694254.001]
  • [Cites] Lab Invest. 1990 Sep;63(3):298-306 [1697637.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1335-9 [1700664.001]
  • [Cites] Annu Rev Physiol. 1991;53:217-39 [1710435.001]
  • [Cites] Exp Pathol. 1990;40(4):301-12 [2098275.001]
  • [Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]
  • [Cites] Virchows Arch. 1998 Jan;432(1):33-42 [9463585.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Dev Comp Immunol. 2001 Apr;25(3):231-43 [11164888.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):635-42 [12068292.001]
  • [Cites] Immunity. 2002 Jun;16(6):803-14 [12121662.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2842-5 [12218095.001]
  • [Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]
  • [Cites] Dev Immunol. 2002 Dec;9(4):223-31 [15144019.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2771-9 [1157049.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] J Mol Biol. 1981 Dec 25;153(4):933-59 [6177862.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):500-7 [6182789.001]
  • [Cites] Cell. 1982 Sep;30(2):361-72 [6183000.001]
  • [Cites] Differentiation. 1983;23(3):256-69 [6189757.001]
  • [Cites] Pathol Res Pract. 1982;175(2-3):256-65 [6190148.001]
  • [Cites] Am J Pathol. 1984 Jan;114(1):121-30 [6197886.001]
  • [Cites] J Pathol. 1983 Nov;141(3):385-413 [6198502.001]
  • [Cites] Lab Invest. 1984 Jan;50(1):36-41 [6198559.001]
  • [Cites] Cell. 1984 Jun;37(2):367-79 [6327063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11822-7 [9751749.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1474-81 [9850173.001]
  • [Cites] Semin Diagn Pathol. 1999 Feb;16(1):2-17 [10355650.001]
  • [Cites] Pathology. 1998 May;30(2):111-22 [9643488.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7 [8356051.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5797-804 [6209004.001]
  • [Cites] Lab Invest. 1985 Jan;52(1):31-8 [2578201.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Mol Cell Biol. 1985 Apr;5(4):642-8 [2985963.001]
  • [Cites] J Natl Cancer Inst. 1985 Aug;75(2):369-79 [3860689.001]
  • [Cites] Nature. 1985 Aug 1-7;316(6027):457-60 [2991771.001]
  • [Cites] Lab Invest. 1986 Nov;55(5):521-30 [2430138.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] J Virol. 1987 Jun;61(6):2029-32 [3033329.001]
  • [Cites] Thymus. 1987;9(2):95-121 [3296336.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3178-84 [3118193.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2699-704 [2824189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(9):3135-9 [2452444.001]
  • [Cites] J Comp Pathol. 1988 Aug;99(2):187-203 [2846660.001]
  • [Cites] Toxicol Pathol. 1988;16(3):321-6 [3194653.001]
  • [Cites] Cell Tissue Res. 1988 Oct;254(1):225-31 [2461804.001]
  • [Cites] Oncogene Res. 1988;3(1):87-97 [3060799.001]
  • [Cites] Annu Rev Genet. 1988;22:479-519 [3071256.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cell. 1989 Sep 8;58(5):803-5 [2673531.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6108-17 [2551499.001]
  • [Cites] Am J Pathol. 1989 Oct;135(4):679-95 [2552813.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Am J Surg Pathol. 1990 Feb;14(2):151-66 [1689123.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):13-24 [1717051.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1161-7 [1957168.001]
  • [Cites] J Clin Invest. 1992 Jan;89(1):244-53 [1729274.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):211-20 [1550962.001]
  • [Cites] Development. 1992 Feb;114(2):521-32 [1592003.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2175-87 [1279498.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):99-105 [7677978.001]
  • [Cites] Cancer Treat Res. 1992;63:359-71 [1284027.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] FASEB J. 1993 Jul;7(10):866-71 [8344486.001]
  • [Cites] Toxicol Pathol. 1993;21(2):206-18 [8210943.001]
  • [Cites] Immunol Today. 1993 Sep;14(9):445-59 [8216723.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]
  • (PMID = 16309545.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Antigens, Viral, Tumor; 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase
  • [Other-IDs] NLM/ PMC2517450
  •  go-up   go-down


100. Lukes P, Pácová H, Kucera T, Veselý D, Martínek J, Astl J: Expression of endothelial and inducible nitric oxide synthase and caspase-3 in tonsillar cancer, chronic tonsillitis and healthy tonsils. Folia Biol (Praha); 2008;54(5):141-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NO, synthesized by NOS, plays an important role in tumour growth, dissemination and vascularization.
  • The presented research work has been focused on the comparative evaluation of localization of the angiogenic and proapoptotic cytokines expressed in tonsillar diseases.
  • However, the positivity in the interfollicular zone and surface squamous epithelium was weak only.
  • Low expression of caspase-3 in malignant epithelial cells of tonsillar cancer shows decreased capability of apoptosis compared to chronic tonsillitis tissue, where apoptosis seems to be rather frequent and concentrated in the germinal centres of lymphatic follicles.
  • The differences in localization of eNOS and caspase-3 expression between benign and malignant processes may be a promising tool for precise morphological distinction of chronic inflammation and tumours.

  • MedlinePlus Health Information. consumer health - Tonsillitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178812.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Cytokines; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 3.4.22.- / Caspase 3
  •  go-up   go-down






Advertisement